WO2024262491A1 - Nrf2活性化作用を有する含窒素複素環化合物の結晶 - Google Patents

Nrf2活性化作用を有する含窒素複素環化合物の結晶 Download PDF

Info

Publication number
WO2024262491A1
WO2024262491A1 PCT/JP2024/022040 JP2024022040W WO2024262491A1 WO 2024262491 A1 WO2024262491 A1 WO 2024262491A1 JP 2024022040 W JP2024022040 W JP 2024022040W WO 2024262491 A1 WO2024262491 A1 WO 2024262491A1
Authority
WO
WIPO (PCT)
Prior art keywords
crystal
powder
compound
diffraction
ray diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2024/022040
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
智哉 岩田
則幸 ▲高▼田
将人 河野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority to KR1020257042624A priority Critical patent/KR20260023529A/ko
Priority to IL324833A priority patent/IL324833A/en
Priority to EP24825892.3A priority patent/EP4696692A1/en
Priority to AU2024314540A priority patent/AU2024314540A1/en
Priority to CN202480033461.0A priority patent/CN121152792A/zh
Priority to JP2025528066A priority patent/JP7904995B2/ja
Publication of WO2024262491A1 publication Critical patent/WO2024262491A1/ja
Priority to MX2025014082A priority patent/MX2025014082A/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention relates to a crystal of a nitrogen-containing heterocyclic compound or a salt thereof, or a solvate thereof, that has an Nrf2 activation effect. It also relates to a medicine and a pharmaceutical composition that contain them as an active ingredient.
  • Nrf2 is a regulator of genes involved in various biological defenses, and a transcription factor that is activated in response to oxidative stress. Under normal conditions, Nrf2 binds to Keap1, is ubiquitinated, and is degraded by the proteasome pathway, but under stressful conditions, it is released from Keap1, avoiding degradation and migrating into the nucleus. Nrf2 then forms a heterodimer with a small Maf group factor, and induces the transcription of downstream molecules by binding to antioxidant response elements (AREs).
  • AREs antioxidant response elements
  • Nrf2 Activation of Nrf2 exhibits a wide range of pharmacological effects, including anti-inflammatory, anti-fibrotic, and anti-apoptotic effects in addition to antioxidant effects, and is thought to act protectively against various diseases.
  • diseases include neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Friedreich's ataxia, and amyotrophic lateral sclerosis, pulmonary diseases such as idiopathic pulmonary fibrosis, acute respiratory distress syndrome, chronic obstructive pulmonary disease, pulmonary arterial hypertension, and asthma, renal diseases such as chronic kidney disease and acute kidney injury, ophthalmic diseases such as uveitis, glaucoma, and age-related macular degeneration, liver diseases such as non-alcoholic steatohepatitis, and immune and inflammatory diseases such as multiple sclerosis, rheumatoid arthritis, and ulcerative colitis (Non-Patent Documents 3 to 7).
  • Non-Patent Document 8 As a compound that actually has an Nrf2 activation-inducing effect, bardoxolone methyl (CDDO-Me, Patent Document 1) is currently undergoing clinical trials for various chronic kidney diseases. In addition, RTA-408 (omaveloxolone, Patent Document 2) has been approved by the FDA for the treatment of Friedreich's ataxia, etc. Dimethyl fumarate (Patent Document 3) is used as a treatment for multiple sclerosis. However, these compounds are compounds that bind covalently to Keap1. Concerns have been reported regarding the risk of heart failure due to interactions between the covalent binding site of bardoxolone methyl and non-target proteins (Non-Patent Document 8).
  • Nrf2 activators compounds such as those described in Patent Document 4 have been reported as Nrf2 activators. However, they have not yet reached clinical development, and there is a need for the development of non-covalent Nrf2 activators that are expected to reduce interactions with non-target proteins (Non-Patent Documents 1 to 3).
  • the object of the present invention is to provide a crystal of a low molecular weight compound, or a salt thereof, or a solvate thereof, which has the ability to activate Nrf2 and reduces interactions with non-target proteins due to covalent bonding. It is also to provide a preventive or therapeutic agent for various diseases, such as neurodegenerative diseases, pulmonary diseases, and renal diseases, which contains the compound or salts as active ingredients.
  • the inventors have conducted intensive research to solve these problems, and have discovered that compounds represented by formulas (1) to (5), or salts thereof, or solvates thereof, which have a chemical structure significantly different from that of known Nrf2 activators, have excellent Nrf2 activating effects, and have discovered crystals of compounds represented by formulas (1) to (5), or salts thereof, or solvates thereof, which have led to the completion of the present invention.
  • [A1] The following formula (1) A crystal of a compound represented by the formula: [A2]
  • [A3] The crystal according to [A1] or [A2], wherein the solvate crystal is a hydrate crystal.
  • [A6-4] The crystal according to [A3], wherein the hydrate crystal is a 1G type crystal having peaks at diffraction angles (2 ⁇ values) of 8.9°, 9.3°, 10.5°, 12.8°, 13.5°, 15.9°, 17.0°, 17.4°, 18.4°, and 19.0° ( ⁇ 0.2°) as determined by powder X-ray diffraction.
  • [A7] The crystal according to any one of [A6] to [A6-4], wherein the diffraction angle (2 ⁇ value) is the diffraction angle (2 ⁇ value) of a hydrate crystal stored at a temperature of 34° C. and a relative humidity of 60% for 5 minutes.
  • [A8-4] The crystal according to [A3], wherein the hydrate crystal is a 1J type crystal having peaks at diffraction angles (2 ⁇ values) of 9.7°, 10.5°, 13.1°, 15.0°, 16.2°, 16.6°, 17.6°, 18.9°, 19.3°, and 20.8° ( ⁇ 0.2°) as determined by powder X-ray diffraction.
  • [A9] The crystal according to any one of [A8] to [A8-4], wherein the diffraction angle (2 ⁇ value) is the diffraction angle (2 ⁇ value) of a hydrate crystal stored at a temperature of 34° C. and a relative humidity of 30% for 15 minutes.
  • [A11-4] The crystal according to [A1] or [A10], wherein the non-solvate crystal is a 1H type crystal having peaks at diffraction angles (2 ⁇ values) of 12.3°, 15.1°, 15.9°, 16.2°, 16.5°, 16.9°, 17.5°, 17.8°, 18.5°, and 19.7° ( ⁇ 0.2°) by powder X-ray diffraction.
  • [A12] The crystal according to any one of [A11] to [A11-4], wherein the diffraction angle (2 ⁇ value) is a diffraction angle (2 ⁇ value) of a water nonsolvate crystal stored at a temperature of 34° C. and 0% relative humidity for 60 minutes.
  • [A13-1] The crystal according to [A1] or [A2], which is a 1K type crystal having at least three peaks selected from the group consisting of 9.5°, 11.3°, 16.3°, 16.6°, 17.6°, 18.4°, 19.1°, 19.9°, 21.0°, and 21.9° ( ⁇ 0.2°) as diffraction angles (2 ⁇ values) by powder X-ray diffraction.
  • [A13-4] The crystal according to [A1] or [A2], which is a 1K type crystal having peaks at diffraction angles (2 ⁇ values) of 9.5°, 11.3°, 16.3°, 16.6°, 17.6°, 18.4°, 19.1°, 19.9°, 21.0°, and 21.9° ( ⁇ 0.2°) as determined by powder X-ray diffraction.
  • [B1] The following formula (2) A crystal of a compound represented by the formula: [B2]
  • [B6-1] The crystal according to [B1] or [B5], which is a 3D type crystal containing at least three peaks selected from the group consisting of 6.6°, 7.3°, 10.9°, 11.8°, 13.9°, 17.1°, 17.5°, 18.3°, 19.3°, and 22.0° ( ⁇ 0.2°) as diffraction angles (2 ⁇ values) by powder X-ray diffraction.
  • [B7-4] The crystal according to [B1] or [B5], which is a 3B type crystal including peaks at diffraction angles (2 ⁇ values) of 7.4°, 14.0°, 14.6°, 15.5°, 17.1°, 18.1°, 19.8°, 21.8°, 22.4°, and 24.1° ( ⁇ 0.2°) by powder X-ray diffraction.
  • [C1] The following formula (3) A crystal of a compound represented by the formula: [C2]
  • the crystal according to [C1] which is a non-solvate crystal of the compound represented by formula (3).
  • [D4-4] The crystal according to [D3], wherein the hydrate crystal is a 5A type crystal having peaks at diffraction angles (2 ⁇ values) of 7.4°, 8.8°, 9.5°, 10.4°, 12.2°, 15.5°, 16.6°, 17.1°, 17.5°, and 18.1° ( ⁇ 0.2°) as determined by powder X-ray diffraction.
  • [D5] The crystal according to [D3], wherein the hydrate crystal is a 5A type crystal having peaks at diffraction angles (2 ⁇ values) of 7.4°, 8.8°, and 9.5° ( ⁇ 0.2°) by powder X-ray diffraction.
  • [D6-1] The crystal according to [D3], wherein the hydrate crystal is a 5A type crystal having at least three peaks selected from the group consisting of 7.4°, 8.8°, 9.5°, 10.8°, 12.7°, 16.0°, 16.8°, 17.3°, 17.9°, and 19.2° ( ⁇ 0.2°) as diffraction angles (2 ⁇ values) by powder X-ray diffraction.
  • [D6-4] The crystal according to [D3], wherein the hydrate crystal is a 5A type crystal having peaks at diffraction angles (2 ⁇ values) of 7.4°, 8.8°, 9.5°, 10.8°, 12.7°, 16.0°, 16.8°, 17.3°, 17.9°, and 19.2° ( ⁇ 0.2°) as determined by powder X-ray diffraction.
  • [D7] The crystal according to any one of [D6] to [D6-4], wherein the diffraction angle (2 ⁇ value) is the diffraction angle (2 ⁇ value) of a hydrate crystal stored at a temperature of 25° C. and a relative humidity of 10% for 1 hour.
  • [D8-1] The crystal according to [D3], wherein the hydrate crystal is a 5A type crystal having at least three peaks selected from the group consisting of 7.4°, 8.8°, 9.5°, 10.5°, 12.2°, 15.6°, 16.6°, 17.1°, 17.3°, and 17.5° ( ⁇ 0.2°) as diffraction angles (2 ⁇ values) by powder X-ray diffraction.
  • [D8-2] The crystal according to [D3], wherein the hydrate crystal is a 5A type crystal having at least five peaks selected from the group consisting of 7.4°, 8.8°, 9.5°, 10.5°, 12.2°, 15.6°, 16.6°, 17.1°, 17.3°, and 17.5° ( ⁇ 0.2°) as diffraction angles (2 ⁇ values) by powder X-ray diffraction.
  • [D8-4] The crystal according to [D3], wherein the hydrate crystal is a 5A type crystal having peaks at diffraction angles (2 ⁇ values) of 7.4°, 8.8°, 9.5°, 10.5°, 12.2°, 15.6°, 16.6°, 17.1°, 17.3°, and 17.5° ( ⁇ 0.2°) as determined by powder X-ray diffraction.
  • [D9] The crystal according to any one of [D8] to [D8-4], wherein the diffraction angle (2 ⁇ value) is the diffraction angle (2 ⁇ value) of a hydrate crystal stored at a temperature of 25° C. and a relative humidity of 20% for 1 hour.
  • [D10-1] The crystal according to [D3], wherein the hydrate crystal is a 5A type crystal having at least three peaks selected from the group consisting of 7.4°, 8.8°, 9.5°, 10.5°, 12.2°, 15.5°, 16.4°, 16.6°, 17.1°, and 17.6° ( ⁇ 0.2°) as diffraction angles (2 ⁇ values) by powder X-ray diffraction.
  • [D10-2] The crystal according to [D3], wherein the hydrate crystal is a 5A type crystal having at least five peaks selected from the group consisting of 7.4°, 8.8°, 9.5°, 10.5°, 12.2°, 15.5°, 16.4°, 16.6°, 17.1°, and 17.6° ( ⁇ 0.2°) as diffraction angles (2 ⁇ values) by powder X-ray diffraction.
  • [D10-4] The crystal according to [D3], wherein the hydrate crystal is a 5A type crystal having peaks at diffraction angles (2 ⁇ values) of 7.4°, 8.8°, 9.5°, 10.5°, 12.2°, 15.5°, 16.4°, 16.6°, 17.1°, and 17.6° ( ⁇ 0.2°) as determined by powder X-ray diffraction.
  • [D11] The crystal according to any one of [D10] to [D10-4], wherein the diffraction angle (2 ⁇ value) is the diffraction angle (2 ⁇ value) of a hydrate crystal stored at a temperature of 25° C. and a relative humidity of 30% for 1 hour.
  • [D12] The crystal according to [D3], wherein the hydrate crystal is a 5A type crystal having at least one peak selected from the group consisting of 7.4°, 8.8°, 9.5°, 10.3°, 12.2°, 15.4°, 16.3°, 16.6°, 17.0°, and 17.6° ( ⁇ 0.2°) as a diffraction angle (2 ⁇ value) by powder X-ray diffraction.
  • [D12-2] The crystal according to [D3], wherein the hydrate crystal is a 5A type crystal having at least five peaks selected from the group consisting of 7.4°, 8.8°, 9.5°, 10.3°, 12.2°, 15.4°, 16.3°, 16.6°, 17.0°, and 17.6° ( ⁇ 0.2°) as diffraction angles (2 ⁇ values) by powder X-ray diffraction.
  • [D12-3] The crystal according to [D3], wherein the hydrate crystal is a 5A type crystal having at least seven peaks selected from the group consisting of 7.4°, 8.8°, 9.5°, 10.3°, 12.2°, 15.4°, 16.3°, 16.6°, 17.0°, and 17.6° ( ⁇ 0.2°) as diffraction angles (2 ⁇ values) by powder X-ray diffraction.
  • [D12-4] The crystal according to [D3], wherein the hydrate crystal is a 5A type crystal having peaks at diffraction angles (2 ⁇ values) of 7.4°, 8.8°, 9.5°, 10.3°, 12.2°, 15.4°, 16.3°, 16.6°, 17.0°, and 17.6° ( ⁇ 0.2°) by powder X-ray diffraction.
  • [D13] The crystal according to any one of [D12] to [D12-4], wherein the diffraction angle (2 ⁇ value) is the diffraction angle (2 ⁇ value) of a hydrate crystal stored at a temperature of 25° C. and a relative humidity of 60% for 1 hour.
  • [D16] The crystal described in [D3], wherein the hydrate crystal is a 5J type crystal having at least one peak selected from the group consisting of 7.3°, 9.0°, 9.6°, 10.9°, 12.3°, 15.9°, 16.6°, 17.1°, and 17.5° ( ⁇ 0.2°) as a diffraction angle (2 ⁇ value) by powder X-ray diffraction.
  • [D16-4] The crystal according to [D3], wherein the hydrate crystal is a 5J type crystal having peaks at diffraction angles (2 ⁇ values) of 7.3°, 9.0°, 9.6°, 10.9°, 12.3°, 15.9°, 16.6°, 17.1°, and 17.5° ( ⁇ 0.2°) by powder X-ray diffraction.
  • [D17] The crystal according to any one of [D16] to [D16-4], wherein the diffraction angle (2 ⁇ value) is the diffraction angle (2 ⁇ value) of a hydrate crystal stored at a temperature of 25° C. and a relative humidity of 30% for 1 hour.
  • [D18-4] The crystal according to [D3], wherein the hydrate crystal is a 5J type crystal having peaks at diffraction angles (2 ⁇ values) of 7.3°, 8.9°, 9.6°, 10.8°, 12.2°, 15.7°, 16.3°, 16.6°, 17.0° and 17.3° ( ⁇ 0.2°) as determined by powder X-ray diffraction.
  • [D19] The crystal according to any one of [D18] to [D18-4], wherein the diffraction angle (2 ⁇ value) is the diffraction angle (2 ⁇ value) of a hydrate crystal stored at a temperature of 25° C. and a relative humidity of 40% for 1 hour.
  • [D20] The crystal according to [D3], wherein the hydrate crystal is a 5J type crystal having at least one peak selected from the group consisting of 7.3°, 8.9°, 9.6°, 10.7°, 12.1°, 15.6°, 16.2°, 16.6°, 16.9° and 17.2° ( ⁇ 0.2°) as a diffraction angle (2 ⁇ value) by powder X-ray diffraction.
  • [D20-2] The crystal according to [D3], wherein the hydrate crystal is a 5J type crystal having at least five peaks selected from the group consisting of 7.3°, 8.9°, 9.6°, 10.7°, 12.1°, 15.6°, 16.2°, 16.6°, 16.9° and 17.2° ( ⁇ 0.2°) as diffraction angles (2 ⁇ values) by powder X-ray diffraction.
  • [D20-4] The crystal according to [D3], wherein the hydrate crystal is a 5J type crystal having peaks at diffraction angles (2 ⁇ values) of 7.3°, 8.9°, 9.6°, 10.7°, 12.1°, 15.6°, 16.2°, 16.6°, 16.9° and 17.2° ( ⁇ 0.2°) as determined by powder X-ray diffraction.
  • [D21] The crystal according to any one of [D20] to [D20-4], wherein the diffraction angle (2 ⁇ value) is the diffraction angle (2 ⁇ value) of a hydrate crystal stored at a temperature of 25° C. and a relative humidity of 50 to 60% for 1 hour.
  • [D24] The crystal according to [D1], which is a non-solvate crystal of the compound represented by formula (4).
  • [D25] The crystal according to [D1] or [D24], which is a 5C type crystal having at least one peak selected from the group consisting of 7.3°, 9.7°, 12.1°, 14.8°, 15.2°, 15.7°, 16.6°, and 17.7° ( ⁇ 0.2°) as a diffraction angle (2 ⁇ value) by powder X-ray diffraction.
  • [D25-1] The crystal according to [D1] or [D24], which is a 5C type crystal containing at least three peaks selected from the group consisting of 7.3°, 9.7°, 12.1°, 14.8°, 15.2°, 15.7°, 16.6°, and 17.7° ( ⁇ 0.2°) as diffraction angles (2 ⁇ values) by powder X-ray diffraction.
  • [D25-3] The crystal according to [D1] or [D24], which is a 5C type crystal containing at least seven peaks selected from the group consisting of 7.3°, 9.7°, 12.1°, 14.8°, 15.2°, 15.7°, 16.6°, and 17.7° ( ⁇ 0.2°) as diffraction angles (2 ⁇ values) by powder X-ray diffraction.
  • [D25-4] The crystal according to [D1] or [D24], which is a 5C type crystal including peaks at diffraction angles (2 ⁇ values) of 7.3°, 9.7°, 12.1°, 14.8°, 15.2°, 15.7°, 16.6°, and 17.7° ( ⁇ 0.2°) by powder X-ray diffraction.
  • the non-solvated crystal is a 5D type crystal containing at least three peaks selected from the group consisting of 11.3°, 13.1°, 13.8°, 14.9°, 15.9°, 16.1°, 16.7°, 17.5°, 18.1°, and 18.5° ( ⁇ 0.2°) as diffraction angles (2 ⁇ values) by powder X-ray diffraction.
  • the non-solvated crystal is a 5D type crystal containing at least five peaks selected from the group consisting of 11.3°, 13.1°, 13.8°, 14.9°, 15.9°, 16.1°, 16.7°, 17.5°, 18.1°, and 18.5° ( ⁇ 0.2°) as diffraction angles (2 ⁇ values) by powder X-ray diffraction.
  • the non-solvated crystal is a 5D type crystal containing at least seven peaks selected from the group consisting of 11.3°, 13.1°, 13.8°, 14.9°, 15.9°, 16.1°, 16.7°, 17.5°, 18.1°, and 18.5° ( ⁇ 0.2°) as diffraction angles (2 ⁇ values) by powder X-ray diffraction.
  • the crystal is a 5G type crystal having at least one peak selected from the group consisting of 9.4°, 11.0°, 13.4°, 15.0°, 16.1°, 17.8°, 18.1°, 19.7°, 20.8°, and 22.0° ( ⁇ 0.2°) as a diffraction angle (2 ⁇ value) by powder X-ray diffraction, the crystal being described in [D1] or [D2].
  • the crystal is a 5G type crystal containing at least five peaks selected from the group consisting of 9.4°, 11.0°, 13.4°, 15.0°, 16.1°, 17.8°, 18.1°, 19.7°, 20.8°, and 22.0° ( ⁇ 0.2°) as diffraction angles (2 ⁇ values) by powder X-ray diffraction.
  • the crystal according to [D1] or [D2] is a 5G type crystal containing at least seven peaks selected from the group consisting of 9.4°, 11.0°, 13.4°, 15.0°, 16.1°, 17.8°, 18.1°, 19.7°, 20.8°, and 22.0° ( ⁇ 0.2°) as diffraction angles (2 ⁇ values) by powder X-ray diffraction.
  • the crystal is a 5G type crystal having peaks at diffraction angles (2 ⁇ values) of 9.4°, 11.0°, 13.4°, 15.0°, 16.1°, 17.8°, 18.1°, 19.7°, 20.8°, and 22.0° ( ⁇ 0.2°) by powder X-ray diffraction, the crystal being described in [D1] or [D2].
  • [E1] The following formula (5) A crystal of a compound represented by the formula: [E2]
  • [E3] The crystal according to [E1] or [E2], wherein the solvate crystal is a hydrate crystal.
  • [E5-1] The crystal according to [E1] or [E2], which is a 4A type crystal comprising at least three peaks selected from the group consisting of 11.5°, 11.8°, 15.7°, 17.2°, 17.5°, 18.1°, 19.5°, 20.3°, 20.5°, and 21.2° ( ⁇ 0.2°) as diffraction angles (2 ⁇ values) in powder X-ray diffraction.
  • [F2] The crystal according to [F1], which is a crystal of a compound or a salt thereof, or a solvate thereof, according to any one of [A1] to [A13-4], [B1] to [B7-4], [C1] to [C6-4], [D1] to [D27-4], and [E1] to [E5-4].
  • [G1] A pharmaceutical composition comprising a crystal of a compound or a salt thereof, or a solvate thereof, according to any one of [A1] to [A13-4], [B1] to [B7-4], [C1] to [C6-4], [D1] to [D27-4], [E1] to [E5-4], and [F1] to [F2].
  • [G2] The pharmaceutical composition described in [G1] for the prevention and/or treatment of a neurodegenerative disease, a pulmonary disease, or a renal disease.
  • [G3] A method for preventing and/or treating a neurodegenerative disease, a pulmonary disease, or a renal disease, comprising administering to a subject an effective amount of a compound or a salt thereof, or a crystal of a solvate thereof, according to any one of [A1] to [A13-4], [B1] to [B7-4], [C1] to [C6-4], [D1] to [D27-4], [E1] to [E5-4], and [F1] to [F2].
  • [G4] A crystal of a compound or a salt thereof, or a solvate thereof, according to any one of [A1] to [A13-4], [B1] to [B7-4], [C1] to [C6-4], [D1] to [D27-4], [E1] to [E5-4], and [F1] to [F2], for use in the prevention and/or treatment of a neurodegenerative disease, a pulmonary disease, or a renal disease.
  • [G5] Use of a crystal of a compound or a salt thereof, or a solvate thereof, according to any one of [A1] to [A13-4], [B1] to [B7-4], [C1] to [C6-4], [D1] to [D27-4], [E1] to [E5-4], and [F1] to [F2], for the manufacture of a pharmaceutical composition for the prevention and/or treatment of a neurodegenerative disease, a pulmonary disease, or a renal disease.
  • a pharmaceutical composition comprising a compound according to any one of [A1] to [A13-4], [B1] to [B7-4], [C1] to [C6-4], [D1] to [D27-4], [E1] to [E5-4], and [F1] to [F2] or a salt thereof, or a crystal of a solvate thereof, mixed with a pharma- ceutically acceptable carrier or vehicle.
  • [G7] A pharmaceutical composition comprising a compound or a salt thereof, or a crystal of a solvate thereof, according to any one of [A1] to [A13-4], [B1] to [B7-4], [C1] to [C6-4], [D1] to [D27-4], [E1] to [E5-4], and [F1] to [F2], dissolved in a pharma- ceutical carrier or medium.
  • the following formulas (1) to (5) A method for producing a pharmaceutical composition containing, as an active ingredient, a compound represented by any one of the following formulas, or a salt thereof, or a solvate thereof:
  • the above-mentioned production method comprises a step of mixing a crystal of a compound or a salt thereof, or a solvate thereof, according to any one of [A1] to [A13-4], [B1] to [B7-4], [C1] to [C6-4], [D1] to [D27-4], and [E1] to [E5-4], with a pharma- ceutically acceptable carrier or medium.
  • [H10] The method according to any one of [H6] to [H9], wherein the step of mixing the compound or a salt thereof, or a solvate thereof with a pharma- ceutically acceptable carrier or medium is a step of dissolving the compound or a salt thereof, or a solvate thereof in the pharma- ceutically acceptable carrier or medium.
  • the numbers referred to in the dependent claims include their subnumbers unless otherwise specified.
  • [A4] referred to in the dependent claims includes [A4] as well as its subnumbers [A4-1], [A4-2], [A4-3], and [A4-4]. The same applies to other numbering schemes.
  • the present invention provides a compound having an Nrf2 activating effect, or a salt thereof, or a crystal of a solvate thereof, which can be used as a preventive or therapeutic agent for various diseases, such as neurodegenerative diseases, pulmonary diseases, and renal diseases.
  • the results of powder X-ray diffraction measurement of the crystals obtained in Example 2-1-1 are shown below.
  • the vertical axis represents the diffraction intensity, and the horizontal axis represents the diffraction angle 2 ⁇ (°).
  • the results of TG-DTA measurement of the crystals obtained in Example 2-1-1 are shown.
  • the vertical axis of (A) is the weight change, and the horizontal axis is the temperature.
  • the vertical axis of (B) is the heat flow, and the horizontal axis is the temperature.
  • the + marks and temperatures on the graph of (B) are the melting point or other transition points.
  • the results of powder X-ray diffraction measurement of the crystals obtained in Example 2-1-3 are shown below.
  • the vertical axis represents the diffraction intensity
  • the horizontal axis represents the diffraction angle 2 ⁇ (°).
  • the results of TG-DTA measurement of the crystals obtained in Example 2-1-3 are shown.
  • the vertical axis of (A) is the weight change, and the horizontal axis is the temperature.
  • the vertical axis of (B) is the heat flow, and the horizontal axis is the temperature.
  • the + marks and temperatures on the graph of (B) are the melting point or other transition points.
  • the results of powder X-ray diffraction measurement under humidity controlled conditions obtained in Example 2-1-4 are shown.
  • the vertical axis is the diffraction intensity
  • the horizontal axis is the diffraction angle 2 ⁇ (°).
  • the relative humidity (RH) of each pattern is shown in the figure.
  • the broad peak near 6.4° is due to the measurement device.
  • the results of powder X-ray diffraction measurement of the crystals obtained in Example 2-1-5 are shown below.
  • the vertical axis represents the diffraction intensity, and the horizontal axis represents the diffraction angle 2 ⁇ (°).
  • the crystal structure of the 1G type crystal described in Example 2-1-6 is shown.
  • the results of powder X-ray diffraction measurement of the crystals obtained in Example 2-2-2 are shown below.
  • the vertical axis represents the diffraction intensity, and the horizontal axis represents the diffraction angle 2 ⁇ (°).
  • the results of powder X-ray diffraction measurement of the crystals obtained in Example 2-2-4 are shown below.
  • the vertical axis represents the diffraction intensity
  • the horizontal axis represents the diffraction angle 2 ⁇ (°).
  • the results of TG-DTA measurement of the crystals obtained in Example 2-2-4 are shown.
  • the vertical axis of (A) is the weight change, and the horizontal axis is the temperature.
  • the vertical axis of (B) is the heat flow, and the horizontal axis is the temperature.
  • the + marks and temperatures on the graph of (B) are the melting points or other transition points.
  • the results of powder X-ray diffraction measurement of the crystals obtained in Example 2-2-5 are shown below.
  • the vertical axis represents the diffraction intensity
  • the horizontal axis represents the diffraction angle 2 ⁇ (°).
  • the results of TG-DTA measurement of the crystals obtained in Example 2-2-5 are shown.
  • the vertical axis of (A) is the weight change, and the horizontal axis is the temperature.
  • the vertical axis of (B) is the heat flow, and the horizontal axis is the temperature.
  • the + marks and temperatures on the graph of (B) are the melting point or other transition points.
  • the results of powder X-ray diffraction measurement of the crystals obtained in Example 2-2-6 are shown below.
  • the vertical axis represents the diffraction intensity
  • the horizontal axis represents the diffraction angle 2 ⁇ (°).
  • the results of TG-DTA measurement of the crystals obtained in Example 2-2-6 are shown.
  • the vertical axis of (A) is the weight change, and the horizontal axis is the temperature.
  • the vertical axis of (B) is the heat flow, and the horizontal axis is the temperature.
  • the + marks and temperatures on the graph of (B) are the melting point or other transition points.
  • 1 shows the results of powder X-ray diffraction measurement of the crystals before vacuum drying obtained in Example 2-3-1.
  • the vertical axis represents the diffraction intensity
  • the horizontal axis represents the diffraction angle 2 ⁇ (°).
  • 1 shows the results of powder X-ray diffraction measurement of the vacuum-dried crystals obtained in Example 2-3-1, in which the vertical axis represents the diffraction intensity and the horizontal axis represents the diffraction angle 2 ⁇ (°).
  • the results of TG-DTA measurement of the crystals obtained in Example 2-3-1 are shown.
  • the vertical axis of (A) is the weight change, and the horizontal axis is the temperature.
  • the vertical axis of (B) is the heat flow, and the horizontal axis is the temperature.
  • the + marks and temperatures on the graph of (B) are the melting point or other transition points.
  • the results of powder X-ray diffraction measurement of the crystals obtained in Example 2-3-2 are shown below.
  • the vertical axis represents the diffraction intensity
  • the horizontal axis represents the diffraction angle 2 ⁇ (°).
  • the results of powder X-ray diffraction measurement of the crystals obtained in Example 2-3-3 are shown below.
  • the vertical axis represents the diffraction intensity
  • the horizontal axis represents the diffraction angle 2 ⁇ (°).
  • the results of TG-DTA measurement of the crystals obtained in Example 2-3-3 are shown below.
  • the vertical axis of (A) is the weight change, and the horizontal axis is the temperature.
  • the vertical axis of (B) is the heat flow, and the horizontal axis is the temperature.
  • the + marks and temperatures on the graph of (B) are the melting point or other transition points.
  • the results of powder X-ray diffraction measurement of the crystals obtained in Example 2-4-1 are shown below.
  • the vertical axis represents the diffraction intensity
  • the horizontal axis represents the diffraction angle 2 ⁇ (°).
  • Example 2-4-2 The crystal structure of the 4B type crystal described in Example 2-4-2 is shown.
  • the results of powder X-ray diffraction measurement of the crystals obtained in Example 2-4-3 are shown below.
  • the vertical axis represents the diffraction intensity, and the horizontal axis represents the diffraction angle 2 ⁇ (°).
  • the results of TG-DTA measurement of the crystals obtained in Example 2-4-3 are shown.
  • the vertical axis of (A) is the weight change, and the horizontal axis is the temperature.
  • the vertical axis of (B) is the heat flow, and the horizontal axis is the temperature.
  • the + marks and temperatures on the graph of (B) are the melting point or other transition points.
  • the results of powder X-ray diffraction measurement of the crystals obtained in Example 2-5-2 are shown below.
  • the vertical axis represents the diffraction intensity, and the horizontal axis represents the diffraction angle 2 ⁇ (°).
  • the results of TG-DTA measurement of the crystals obtained in Example 2-5-2 are shown below.
  • the vertical axis of (A) is the weight change, and the horizontal axis is the temperature.
  • the vertical axis of (B) is the heat flow, and the horizontal axis is the temperature.
  • the + marks and temperatures on the graph of (B) are the melting point or other transition points. 1 shows the results of powder X-ray diffraction measurement of the crystals before vacuum drying obtained in Example 2-5-3.
  • the vertical axis represents the diffraction intensity
  • the horizontal axis represents the diffraction angle 2 ⁇ (°).
  • the results of TG-DTA measurement of the crystals obtained in Example 2-5-3 before vacuum drying are shown.
  • the vertical axis of (A) is the weight change, and the horizontal axis is the temperature.
  • the vertical axis of (B) is the heat flow, and the horizontal axis is the temperature.
  • the + marks and temperatures on the graph of (B) are the melting point or other transition points.
  • 1 shows the results of powder X-ray diffraction measurement of the vacuum-dried crystals obtained in Example 2-5-3.
  • the vertical axis represents the diffraction intensity
  • the horizontal axis represents the diffraction angle 2 ⁇ (°).
  • Example 2-5-4 The results of powder X-ray diffraction measurement under various humidity conditions obtained in Example 2-5-4 are shown below.
  • the vertical axis indicates the diffraction intensity, and the horizontal axis indicates the diffraction angle 2 ⁇ (°).
  • the relative humidity (RH) of each pattern is shown in the figure.
  • the results of powder X-ray diffraction measurement (first and second times) under a relative humidity (RH) condition of 60% obtained in Example 2-5-4 are shown.
  • the vertical axis is the diffraction intensity
  • the horizontal axis is the diffraction angle 2 ⁇ (°).
  • the RH and measurement timing of each pattern are shown in the figure.
  • the broad peak near 6.4° is due to the measurement device.
  • Example 2-5-5 The results of powder X-ray diffraction measurement of the crystals obtained in Example 2-5-5 are shown below.
  • the vertical axis represents the diffraction intensity, and the horizontal axis represents the diffraction angle 2 ⁇ (°).
  • the results of powder X-ray diffraction measurement of the crystals obtained in Example 2-5-6 are shown below.
  • the vertical axis represents the diffraction intensity, and the horizontal axis represents the diffraction angle 2 ⁇ (°).
  • the crystal structure of the 5A type crystal described in Example 2-5-6 is shown.
  • the results of powder X-ray diffraction measurement under a relative humidity of 5% obtained in Example 2-5-8 are shown.
  • the vertical axis is the diffraction intensity
  • the horizontal axis is the diffraction angle 2 ⁇ (°).
  • the broad peak near 6.4° is due to the measurement device. Representative powder X-ray diffraction measurement results obtained in Examples 2-5-9 under various humidity conditions are shown below. The vertical axis indicates the diffraction intensity, and the horizontal axis indicates the diffraction angle 2 ⁇ (°). The relative humidity (RH) of each pattern is shown in the figure. The broad peak near 6.4° is due to the measurement device.
  • the present invention relates to a crystal of a compound represented by formulas (1) to (5) or a salt thereof, or a solvate thereof.
  • Specific examples of the crystal of this compound include a nonsolvate crystal or a solvate crystal of this compound, or a nonsolvate crystal or a solvate crystal of a salt of this compound.
  • the solvate crystal include a hydrate crystal, an acetone hydrate crystal, a dimethylsulfoxide (DMSO) hydrate crystal, a dimethylformamide (DMF) hydrate crystal, an acetonitrile hydrate crystal, a tetrahydrofuran hydrate crystal, a methyl ethyl ketone hydrate crystal, a methyl isobutyl ketone hydrate crystal, an ethyl acetate hydrate crystal, a heptane hydrate crystal, a polyethylene glycol (PEG) hydrate crystal, a 2-propanol hydrate crystal, a methanol hydrate crystal, or an ethanol hydrate crystal, and preferably a hydrate crystal.
  • DMSO dimethylsulfoxide
  • DMF dimethylformamide
  • PEG polyethylene glycol
  • salts of compounds include, for example, hydrochlorides; hydrobromides; hydroiodides; phosphates; phosphonates; sulfates; sulfonates such as methanesulfonates and p-toluenesulfonates; carboxylates such as acetates, citrates, malates, tartrates, succinates, and salicylates; or alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as magnesium salts and calcium salts; ammonium salts such as ammonium salts, alkylammonium salts, dialkylammonium salts, trialkylammonium salts, and tetraalkylammonium salts.
  • solvate refers to a compound that forms a molecular group together with a solvent, and is not particularly limited as long as it is a solvate formed with a solvent that is acceptable for ingestion accompanying administration of a medicine.
  • examples of solvates include hydrates, alcohol solvates (ethanol solvates, methanol solvates, 1-propanol solvates, 2-propanol solvates, etc.), and solvates with a single solvent such as dimethyl sulfoxide, as well as solvates formed with multiple solvents per molecule of the compound, or solvates formed with multiple types of solvents per molecule of the compound.
  • the solvent is water, it is called a hydrate.
  • hydrates are preferred, and specific examples of such hydrates include monohydrates to decahydrates, preferably monohydrates to pentahydrates, and more preferably monohydrates to trihydrates.
  • the diffraction angle 2 ⁇ in powder X-ray diffraction is the diffraction peak measured using CuK ⁇ or CuK ⁇ 1 radiation.
  • These solvate crystals further specified by the diffraction angle 2 ⁇ in powder X-ray diffraction are sometimes called “type 1A crystals" of the hydrate shown below, for example, but are sometimes simply called “type 1A”.
  • the hydrate crystal of the compound of formula (1) is a 1A type crystal having at least five of the following peaks in powder X-ray diffraction at a diffraction angle 2 ⁇ : 6.0°, 9.3°, 9.7°, 10.4°, 11.9°, 12.9°, 15.3°, 15.9°, 16.4°, and 16.8° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (1) is a 1A type crystal having at least seven of the following peaks in powder X-ray diffraction as a diffraction angle 2 ⁇ : 6.0°, 9.3°, 9.7°, 10.4°, 11.9°, 12.9°, 15.3°, 15.9°, 16.4°, and 16.8° ( ⁇ 0.2°).
  • the hydrate crystal of the compound of formula (1) is a 1G type crystal having at least three of the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction: 8.8°, 9.2°, 10.4°, 12.7°, 13.4°, 15.8°, 16.9°, 17.3°, 18.3°, and 18.9° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (1) is a 1G type crystal having at least five of the following peaks in powder X-ray diffraction at a diffraction angle 2 ⁇ : 8.8°, 9.2°, 10.4°, 12.7°, 13.4°, 15.8°, 16.9°, 17.3°, 18.3°, and 18.9° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (1) is a 1G type crystal having at least seven of the following peaks in powder X-ray diffraction at a diffraction angle 2 ⁇ : 8.8°, 9.2°, 10.4°, 12.7°, 13.4°, 15.8°, 16.9°, 17.3°, 18.3°, and 18.9° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (1) is a 1G type crystal having the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction: 8.8°, 9.2°, 10.4°, 12.7°, 13.4°, 15.8°, 16.9°, 17.3°, 18.3°, and 18.9° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (1) is a 1G type crystal having at least one of the following peaks as a diffraction angle 2 ⁇ in powder X-ray diffraction:
  • the following diffraction angles (2 ⁇ values) are preferably those of the hydrate crystal stored at a temperature of 34° C. and a relative humidity of 60% for 5 minutes. 8.9°, 9.3°, 10.5°, 12.8°, 13.5°, 15.9°, 17.0°, 17.4°, 18.4°, and 19.0° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (1) is a 1G type crystal that contains at least three of the following peaks as diffraction angles 2 ⁇ in powder X-ray diffraction.
  • the following diffraction angles (2 ⁇ values) are preferably those of the hydrate crystal stored at a temperature of 34° C. and a relative humidity of 60% for 5 minutes. 8.9°, 9.3°, 10.5°, 12.8°, 13.5°, 15.9°, 17.0°, 17.4°, 18.4°, and 19.0° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (1) is a 1G type crystal that contains at least five of the following peaks as diffraction angles 2 ⁇ in powder X-ray diffraction.
  • the following diffraction angles (2 ⁇ values) are preferably those of the hydrate crystal stored at a temperature of 34° C. and a relative humidity of 60% for 5 minutes. 8.9°, 9.3°, 10.5°, 12.8°, 13.5°, 15.9°, 17.0°, 17.4°, 18.4°, and 19.0° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (1) is a 1G type crystal that contains at least seven of the following peaks as diffraction angles 2 ⁇ in powder X-ray diffraction.
  • the following diffraction angles (2 ⁇ values) are preferably those of the hydrate crystal stored at a temperature of 34° C. and a relative humidity of 60% for 5 minutes. 8.9°, 9.3°, 10.5°, 12.8°, 13.5°, 15.9°, 17.0°, 17.4°, 18.4°, and 19.0° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (1) is a 1G-type crystal having the following peaks as diffraction angles 2 ⁇ in powder X-ray diffraction:
  • the following diffraction angles (2 ⁇ values) are preferably those of the hydrate crystal stored at a temperature of 34° C. and a relative humidity of 60% for 5 minutes. 8.9°, 9.3°, 10.5°, 12.8°, 13.5°, 15.9°, 17.0°, 17.4°, 18.4°, and 19.0° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (1) is a 1J-type crystal that contains at least one of the following peaks as a diffraction angle 2 ⁇ in powder X-ray diffraction.
  • the following diffraction angle (2 ⁇ value) may be the diffraction angle (2 ⁇ value) of the hydrate crystal stored at a temperature of 34° C. and a relative humidity of 30% for 15 minutes. 9.7°, 10.5°, 13.1°, 15.0°, 16.2°, 16.6°, 17.6°, 18.9°, 19.3°, and 20.8° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (1) is a 1J-type crystal that contains at least three of the following peaks as diffraction angles 2 ⁇ in powder X-ray diffraction.
  • the following diffraction angles (2 ⁇ values) may be the diffraction angles (2 ⁇ values) of the hydrate crystal stored at a temperature of 34° C. and a relative humidity of 30% for 15 minutes. 9.7°, 10.5°, 13.1°, 15.0°, 16.2°, 16.6°, 17.6°, 18.9°, 19.3°, and 20.8° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (1) is a 1J-type crystal that contains at least five of the following peaks as diffraction angles 2 ⁇ in powder X-ray diffraction.
  • the following diffraction angles (2 ⁇ values) may be the diffraction angles (2 ⁇ values) of the hydrate crystal stored at a temperature of 34° C. and a relative humidity of 30% for 15 minutes. 9.7°, 10.5°, 13.1°, 15.0°, 16.2°, 16.6°, 17.6°, 18.9°, 19.3°, and 20.8° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (1) is a 1J-type crystal that contains at least seven of the following peaks as diffraction angles 2 ⁇ in powder X-ray diffraction.
  • the following diffraction angles (2 ⁇ values) may be the diffraction angles (2 ⁇ values) of the hydrate crystal stored at a temperature of 34° C. and a relative humidity of 30% for 15 minutes. 9.7°, 10.5°, 13.1°, 15.0°, 16.2°, 16.6°, 17.6°, 18.9°, 19.3°, and 20.8° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (1) is a 1J-type crystal having the following peaks as diffraction angles 2 ⁇ in powder X-ray diffraction:
  • the following diffraction angles (2 ⁇ values) may be the diffraction angles (2 ⁇ values) of the hydrate crystal stored at a temperature of 34° C. and a relative humidity of 30% for 15 minutes. 9.7°, 10.5°, 13.1°, 15.0°, 16.2°, 16.6°, 17.6°, 18.9°, 19.3°, and 20.8° ( ⁇ 0.2°)
  • the nonsolvate crystal of the compound of formula (1) is a 1H type crystal that contains at least one of the following peaks as a diffraction angle 2 ⁇ in powder X-ray diffraction.
  • the following diffraction angle (2 ⁇ value) may be the diffraction angle (2 ⁇ value) of the nonsolvate crystal stored at a temperature of 34° C. and 0% relative humidity for 60 minutes. 12.3°, 15.1°, 15.9°, 16.2°, 16.5°, 16.9°, 17.5°, 17.8°, 18.5°, and 19.7° ( ⁇ 0.2°)
  • the nonsolvate crystal of the compound of formula (1) is a 1H type crystal that contains at least three of the following peaks as diffraction angles 2 ⁇ in powder X-ray diffraction.
  • the following diffraction angles (2 ⁇ values) may be the diffraction angles (2 ⁇ values) of the nonsolvate crystal stored at a temperature of 34° C. and 0% relative humidity for 60 minutes. 12.3°, 15.1°, 15.9°, 16.2°, 16.5°, 16.9°, 17.5°, 17.8°, 18.5°, and 19.7° ( ⁇ 0.2°)
  • the nonsolvate crystal of the compound of formula (1) is a 1H type crystal that contains at least five of the following peaks as diffraction angles 2 ⁇ in powder X-ray diffraction.
  • the following diffraction angles (2 ⁇ values) may be the diffraction angles (2 ⁇ values) of the nonsolvate crystal stored at a temperature of 34° C. and 0% relative humidity for 60 minutes. 12.3°, 15.1°, 15.9°, 16.2°, 16.5°, 16.9°, 17.5°, 17.8°, 18.5°, and 19.7° ( ⁇ 0.2°)
  • the nonsolvate crystal of the compound of formula (1) is a 1H type crystal that contains at least seven of the following peaks as diffraction angles 2 ⁇ in powder X-ray diffraction.
  • the following diffraction angles (2 ⁇ values) may be the diffraction angles (2 ⁇ values) of the nonsolvate crystal stored at a temperature of 34° C. and 0% relative humidity for 60 minutes. 12.3°, 15.1°, 15.9°, 16.2°, 16.5°, 16.9°, 17.5°, 17.8°, 18.5°, and 19.7° ( ⁇ 0.2°)
  • the nonsolvate crystal of the compound of formula (1) is a 1H type crystal having the following peak as a diffraction angle 2 ⁇ in powder X-ray diffraction:
  • the following diffraction angle (2 ⁇ value) may be the diffraction angle (2 ⁇ value) of the nonsolvate crystal stored at a temperature of 34° C. and 0% relative humidity for 60 minutes. 12.3°, 15.1°, 15.9°, 16.2°, 16.5°, 16.9°, 17.5°, 17.8°, 18.5°, and 19.7° ( ⁇ 0.2°)
  • the crystal of the compound of formula (1) is a 1K type crystal having at least one of the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction: 9.5°, 11.3°, 16.3°, 16.6°, 17.6°, 18.4°, 19.1°, 19.9°, 21.0°, and 21.9° ( ⁇ 0.2°)
  • the crystal of the compound of formula (1) is a 1K type crystal having at least three of the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction: 9.5°, 11.3°, 16.3°, 16.6°, 17.6°, 18.4°, 19.1°, 19.9°, 21.0°, and 21.9° ( ⁇ 0.2°)
  • the crystal of the compound of formula (1) is a 1K type crystal having at least five of the following peaks in powder X-ray diffraction at a diffraction angle 2 ⁇ : 9.5°, 11.3°, 16.3°, 16.6°, 17.6°, 18.4°, 19.1°, 19.9°, 21.0°, and 21.9° ( ⁇ 0.2°)
  • the crystal of the compound of formula (1) is a 1K type crystal having at least seven of the following peaks in powder X-ray diffraction at a diffraction angle 2 ⁇ : 9.5°, 11.3°, 16.3°, 16.6°, 17.6°, 18.4°, 19.1°, 19.9°, 21.0°, and 21.9° ( ⁇ 0.2°)
  • the crystal of the compound of formula (1) is a 1K type crystal having the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction. 9.5°, 11.3°, 16.3°, 16.6°, 17.6°, 18.4°, 19.1°, 19.9°, 21.0°, and 21.9° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (2) is a 3A type crystal having at least one of the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction: 10.4°, 12.6°, 15.1°, 15.9°, 16.6°, 17.1°, 18.4°, 19.6°, 19.9°, and 20.6° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (2) is a 3A type crystal comprising at least three of the following peaks in powder X-ray diffraction as a diffraction angle 2 ⁇ : 10.4°, 12.6°, 15.1°, 15.9°, 16.6°, 17.1°, 18.4°, 19.6°, 19.9°, and 20.6° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (2) is a 3A type crystal having at least five of the following peaks in powder X-ray diffraction as a diffraction angle 2 ⁇ : 10.4°, 12.6°, 15.1°, 15.9°, 16.6°, 17.1°, 18.4°, 19.6°, 19.9°, and 20.6° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (2) is a 3A type crystal that contains at least seven of the following peaks in powder X-ray diffraction as a diffraction angle 2 ⁇ : 10.4°, 12.6°, 15.1°, 15.9°, 16.6°, 17.1°, 18.4°, 19.6°, 19.9°, and 20.6° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (2) is a 3A type crystal having the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction. 10.4°, 12.6°, 15.1°, 15.9°, 16.6°, 17.1°, 18.4°, 19.6°, 19.9°, and 20.6° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (2) is a 3C type crystal having at least one of the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction: 7.9°, 8.5°, 8.8°, 9.2°, 10.4°, 11.4°, 12.0°, 13.1°, 15.2°, and 15.7° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (2) is a 3C type crystal comprising at least three of the following peaks in powder X-ray diffraction as a diffraction angle 2 ⁇ : 7.9°, 8.5°, 8.8°, 9.2°, 10.4°, 11.4°, 12.0°, 13.1°, 15.2°, and 15.7° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (2) is a 3C type crystal having at least five of the following peaks as a diffraction angle 2 ⁇ in powder X-ray diffraction: 7.9°, 8.5°, 8.8°, 9.2°, 10.4°, 11.4°, 12.0°, 13.1°, 15.2°, and 15.7° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (2) is a 3C type crystal having the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction. 7.9°, 8.5°, 8.8°, 9.2°, 10.4°, 11.4°, 12.0°, 13.1°, 15.2°, and 15.7° ( ⁇ 0.2°)
  • the crystal of the compound of formula (2) is a 3B type crystal having at least five of the following peaks as a diffraction angle 2 ⁇ in powder X-ray diffraction: 7.4°, 14.0°, 14.6°, 15.5°, 17.1°, 18.1°, 19.8°, 21.8°, 22.4°, and 24.1° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (3) is a 2B type crystal comprising at least three of the following peaks in powder X-ray diffraction as a diffraction angle 2 ⁇ : 7.2°, 7.6°, 13.4°, 14.5°, 16.0°, 16.6°, 17.3°, 19.9°, 20.6°, and 22.4° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (3) is a 2B type crystal comprising at least five of the following peaks in powder X-ray diffraction as a diffraction angle 2 ⁇ : 7.2°, 7.6°, 13.4°, 14.5°, 16.0°, 16.6°, 17.3°, 19.9°, 20.6°, and 22.4° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (3) is a 2B type crystal comprising at least seven of the following peaks as a diffraction angle 2 ⁇ in powder X-ray diffraction: 7.2°, 7.6°, 13.4°, 14.5°, 16.0°, 16.6°, 17.3°, 19.9°, 20.6°, and 22.4° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (3) is a 2B type crystal having the following peaks as a diffraction angle 2 ⁇ in powder X-ray diffraction. 7.2°, 7.6°, 13.4°, 14.5°, 16.0°, 16.6°, 17.3°, 19.9°, 20.6°, and 22.4° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (3) is a 2A type crystal having at least one of the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction: 7.5°, 10.0°, 10.7°, 13.7°, 14.6°, 15.1°, 16.8°, 17.4°, 18.0°, and 18.5° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (3) is a 2A type crystal comprising at least three of the following peaks in powder X-ray diffraction as a diffraction angle 2 ⁇ : 7.5°, 10.0°, 10.7°, 13.7°, 14.6°, 15.1°, 16.8°, 17.4°, 18.0°, and 18.5° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (3) is a 2A type crystal having at least five of the following peaks in powder X-ray diffraction as a diffraction angle 2 ⁇ : 7.5°, 10.0°, 10.7°, 13.7°, 14.6°, 15.1°, 16.8°, 17.4°, 18.0°, and 18.5° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (3) is a 2A type crystal having at least seven of the following peaks as a diffraction angle 2 ⁇ in powder X-ray diffraction: 7.5°, 10.0°, 10.7°, 13.7°, 14.6°, 15.1°, 16.8°, 17.4°, 18.0°, and 18.5° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (3) is a 2A type crystal having the following peaks as a diffraction angle 2 ⁇ in powder X-ray diffraction. 7.5°, 10.0°, 10.7°, 13.7°, 14.6°, 15.1°, 16.8°, 17.4°, 18.0°, and 18.5° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (3) is a 2C type crystal having at least one of the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction: 7.2°, 9.9°, 14.5°, 15.3°, 15.7°, 17.2°, 17.6°, 18.0°, 19.1°, and 19.8° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (3) is a 2C type crystal comprising at least three of the following peaks in powder X-ray diffraction as a diffraction angle 2 ⁇ : 7.2°, 9.9°, 14.5°, 15.3°, 15.7°, 17.2°, 17.6°, 18.0°, 19.1°, and 19.8° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (3) is a 2C type crystal that contains at least seven of the following peaks in powder X-ray diffraction as a diffraction angle 2 ⁇ : 7.2°, 9.9°, 14.5°, 15.3°, 15.7°, 17.2°, 17.6°, 18.0°, 19.1°, and 19.8° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (3) is a 2C type crystal having the following peaks as a diffraction angle 2 ⁇ in powder X-ray diffraction. 7.2°, 9.9°, 14.5°, 15.3°, 15.7°, 17.2°, 17.6°, 18.0°, 19.1°, and 19.8° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (3) is a 2F type crystal having at least one of the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction: 7.3°, 9.9°, 11.4°, 14.5°, 15.3°, 16.4°, 16.8°, 17.2°, 17.7°, and 18.1° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (3) is a 2F type crystal comprising at least three of the following peaks in powder X-ray diffraction at a diffraction angle 2 ⁇ : 7.3°, 9.9°, 11.4°, 14.5°, 15.3°, 16.4°, 16.8°, 17.2°, 17.7°, and 18.1° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (3) is a 2F type crystal having at least five of the following peaks in powder X-ray diffraction as a diffraction angle 2 ⁇ : 7.3°, 9.9°, 11.4°, 14.5°, 15.3°, 16.4°, 16.8°, 17.2°, 17.7°, and 18.1° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (3) is a 2F type crystal that contains at least seven of the following peaks in powder X-ray diffraction as a diffraction angle 2 ⁇ : 7.3°, 9.9°, 11.4°, 14.5°, 15.3°, 16.4°, 16.8°, 17.2°, 17.7°, and 18.1° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (3) is a 2F type crystal having the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction. 7.3°, 9.9°, 11.4°, 14.5°, 15.3°, 16.4°, 16.8°, 17.2°, 17.7°, and 18.1° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5A type crystal having at least one of the following peaks in powder X-ray diffraction at a diffraction angle 2 ⁇ : 7.4°, 8.8°, 9.5°, 10.4°, 12.2°, 15.5°, 16.6°, 17.1°, 17.5°, and 18.1° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5A type crystal having at least three of the following peaks in powder X-ray diffraction at a diffraction angle 2 ⁇ : 7.4°, 8.8°, 9.5°, 10.4°, 12.2°, 15.5°, 16.6°, 17.1°, 17.5°, and 18.1° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5A type crystal having at least five of the following peaks in powder X-ray diffraction as a diffraction angle 2 ⁇ : 7.4°, 8.8°, 9.5°, 10.4°, 12.2°, 15.5°, 16.6°, 17.1°, 17.5°, and 18.1° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5A type crystal having at least seven of the following peaks as a diffraction angle 2 ⁇ in powder X-ray diffraction: 7.4°, 8.8°, 9.5°, 10.4°, 12.2°, 15.5°, 16.6°, 17.1°, 17.5°, and 18.1° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5A type crystal having the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction. 7.4°, 8.8°, 9.5°, 10.4°, 12.2°, 15.5°, 16.6°, 17.1°, 17.5°, and 18.1° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5A type crystal having the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction. 7.4°, 8.8°, and 9.5° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5A type crystal having at least one of the following peaks as a diffraction angle 2 ⁇ in powder X-ray diffraction:
  • the following diffraction angle (2 ⁇ value) may be the diffraction angle (2 ⁇ value) of the hydrate crystal stored at a temperature of 25° C. and a relative humidity of 10% for 1 hour. 7.4°, 8.8°, 9.5°, 10.8°, 12.7°, 16.0°, 16.8°, 17.3°, 17.9°, and 19.2° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5A type crystal having at least three of the following peaks as diffraction angles 2 ⁇ in powder X-ray diffraction.
  • the following diffraction angles (2 ⁇ values) may be the diffraction angles (2 ⁇ values) of the hydrate crystal stored at a temperature of 25° C. and a relative humidity of 10% for 1 hour. 7.4°, 8.8°, 9.5°, 10.8°, 12.7°, 16.0°, 16.8°, 17.3°, 17.9°, and 19.2° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5A type crystal having at least five of the following peaks as diffraction angles 2 ⁇ in powder X-ray diffraction.
  • the following diffraction angles (2 ⁇ values) may be the diffraction angles (2 ⁇ values) of the hydrate crystal stored at a temperature of 25° C. and a relative humidity of 10% for 1 hour. 7.4°, 8.8°, 9.5°, 10.8°, 12.7°, 16.0°, 16.8°, 17.3°, 17.9°, and 19.2° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5A type crystal having at least seven of the following peaks as diffraction angles 2 ⁇ in powder X-ray diffraction.
  • the following diffraction angles (2 ⁇ values) may be the diffraction angles (2 ⁇ values) of the hydrate crystal stored at a temperature of 25° C. and a relative humidity of 10% for 1 hour. 7.4°, 8.8°, 9.5°, 10.8°, 12.7°, 16.0°, 16.8°, 17.3°, 17.9°, and 19.2° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5A type crystal having the following peaks as diffraction angles 2 ⁇ in powder X-ray diffraction:
  • the following diffraction angles (2 ⁇ values) may be the diffraction angles (2 ⁇ values) of the hydrate crystal stored at a temperature of 25° C. and a relative humidity of 10% for 1 hour. 7.4°, 8.8°, 9.5°, 10.8°, 12.7°, 16.0°, 16.8°, 17.3°, 17.9°, and 19.2° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5A type crystal having at least one of the following peaks as a diffraction angle 2 ⁇ in powder X-ray diffraction:
  • the following diffraction angle (2 ⁇ value) may be the diffraction angle (2 ⁇ value) of the hydrate crystal stored at a temperature of 25° C. and a relative humidity of 20% for 1 hour. 7.4°, 8.8°, 9.5°, 10.5°, 12.2°, 15.6°, 16.6°, 17.1°, 17.3°, and 17.5° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5A type crystal that contains at least three of the following peaks as diffraction angles 2 ⁇ in powder X-ray diffraction.
  • the following diffraction angles (2 ⁇ values) may be the diffraction angles (2 ⁇ values) of the hydrate crystal stored at a temperature of 25° C. and a relative humidity of 20% for 1 hour. 7.4°, 8.8°, 9.5°, 10.5°, 12.2°, 15.6°, 16.6°, 17.1°, 17.3°, and 17.5° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5A type crystal having at least five of the following peaks as diffraction angles 2 ⁇ in powder X-ray diffraction.
  • the following diffraction angles (2 ⁇ values) may be the diffraction angles (2 ⁇ values) of the hydrate crystal stored at a temperature of 25° C. and a relative humidity of 20% for 1 hour. 7.4°, 8.8°, 9.5°, 10.5°, 12.2°, 15.6°, 16.6°, 17.1°, 17.3°, and 17.5° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5E type crystal having at least five of the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction: 9.2°, 10.6°, 11.9°, 13.7°, 15.0°, 15.8°, 16.6°, 17.1°, 18.5°, and 19.2° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5J type crystal that contains at least five of the following peaks as diffraction angles 2 ⁇ in powder X-ray diffraction.
  • the following diffraction angles (2 ⁇ values) may be the diffraction angles (2 ⁇ values) of the hydrate crystal stored at a temperature of 25° C. and a relative humidity of 30% for 1 hour. 7.3°, 9.0°, 9.6°, 10.9°, 12.3°, 15.9°, 16.6°, 17.1°, and 17.5° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5J type crystal that contains at least seven of the following peaks as diffraction angles 2 ⁇ in powder X-ray diffraction.
  • the following diffraction angles (2 ⁇ values) may be the diffraction angles (2 ⁇ values) of the hydrate crystal stored at a temperature of 25° C. and a relative humidity of 30% for 1 hour. 7.3°, 9.0°, 9.6°, 10.9°, 12.3°, 15.9°, 16.6°, 17.1°, and 17.5° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5J type crystal having at least one of the following peaks as a diffraction angle 2 ⁇ in powder X-ray diffraction:
  • the following diffraction angle (2 ⁇ value) may be the diffraction angle (2 ⁇ value) of the hydrate crystal stored at a temperature of 25° C. and a relative humidity of 40% for 1 hour. 7.3°, 8.9°, 9.6°, 10.8°, 12.2°, 15.7°, 16.3°, 16.6°, 17.0° and 17.3° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5J type crystal that contains at least three of the following peaks as diffraction angles 2 ⁇ in powder X-ray diffraction.
  • the following diffraction angles (2 ⁇ values) may be the diffraction angles (2 ⁇ values) of the hydrate crystal stored at a temperature of 25° C. and a relative humidity of 50 to 60% for 1 hour. 7.3°, 8.9°, 9.6°, 10.7°, 12.1°, 15.6°, 16.2°, 16.6°, 16.9° and 17.2° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5J type crystal that contains at least five of the following peaks as diffraction angles 2 ⁇ in powder X-ray diffraction.
  • the following diffraction angles (2 ⁇ values) may be the diffraction angles (2 ⁇ values) of the hydrate crystal stored at a temperature of 25° C. and a relative humidity of 50 to 60% for 1 hour. 7.3°, 8.9°, 9.6°, 10.7°, 12.1°, 15.6°, 16.2°, 16.6°, 16.9° and 17.2° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5J type crystal that contains at least seven of the following peaks as diffraction angles 2 ⁇ in powder X-ray diffraction.
  • the following diffraction angles (2 ⁇ values) may be the diffraction angles (2 ⁇ values) of the hydrate crystal stored at a temperature of 25° C. and a relative humidity of 50 to 60% for 1 hour. 7.3°, 8.9°, 9.6°, 10.7°, 12.1°, 15.6°, 16.2°, 16.6°, 16.9° and 17.2° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5J type crystal having the following peak as a diffraction angle 2 ⁇ in powder X-ray diffraction:
  • the following diffraction angle (2 ⁇ value) may be the diffraction angle (2 ⁇ value) of the hydrate crystal stored at a temperature of 25° C. and a relative humidity of 50 to 60% for 1 hour. 7.3°, 8.9°, 9.6°, 10.7°, 12.1°, 15.6°, 16.2°, 16.6°, 16.9° and 17.2° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5J type crystal having at least one of the following peaks as a diffraction angle 2 ⁇ in powder X-ray diffraction:
  • the following diffraction angle (2 ⁇ value) may be the diffraction angle (2 ⁇ value) of the hydrate crystal stored at a temperature of 25° C. and a relative humidity of 70% or more for 1 hour. 7.2°, 8.9°, 9.5°, 10.6°, 12.0°, 15.5°, 16.1°, 16.6°, and 17.1° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5J type crystal that contains at least three of the following peaks as diffraction angles 2 ⁇ in powder X-ray diffraction.
  • the following diffraction angles (2 ⁇ values) may be the diffraction angles (2 ⁇ values) of the hydrate crystal stored at a temperature of 25° C. and a relative humidity of 70% or more for 1 hour. 7.2°, 8.9°, 9.5°, 10.6°, 12.0°, 15.5°, 16.1°, 16.6°, and 17.1° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5J type crystal that contains at least five of the following peaks as diffraction angles 2 ⁇ in powder X-ray diffraction.
  • the following diffraction angles (2 ⁇ values) may be the diffraction angles (2 ⁇ values) of the hydrate crystal stored at a temperature of 25° C. and a relative humidity of 70% or more for 1 hour. 7.2°, 8.9°, 9.5°, 10.6°, 12.0°, 15.5°, 16.1°, 16.6°, and 17.1° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5J type crystal that contains at least seven of the following peaks as diffraction angles 2 ⁇ in powder X-ray diffraction.
  • the following diffraction angles (2 ⁇ values) may be the diffraction angles (2 ⁇ values) of the hydrate crystal stored at a temperature of 25° C. and a relative humidity of 70% or more for 1 hour. 7.2°, 8.9°, 9.5°, 10.6°, 12.0°, 15.5°, 16.1°, 16.6°, and 17.1° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (4) is a 5J type crystal having the following peak as a diffraction angle 2 ⁇ in powder X-ray diffraction:
  • the following diffraction angle (2 ⁇ value) may be the diffraction angle (2 ⁇ value) of the hydrate crystal stored at a temperature of 25° C. and a relative humidity of 70% or more for 1 hour. 7.2°, 8.9°, 9.5°, 10.6°, 12.0°, 15.5°, 16.1°, 16.6°, and 17.1° ( ⁇ 0.2°)
  • the crystal of the compound of formula (4) is a 5C type crystal having at least one of the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction: 7.3°, 9.7°, 12.1°, 14.8°, 15.2°, 15.7°, 16.6°, and 17.7° ( ⁇ 0.2°)
  • the crystal of the compound of formula (4) is a 5C type crystal having at least three of the following peaks in powder X-ray diffraction at a diffraction angle 2 ⁇ : 7.3°, 9.7°, 12.1°, 14.8°, 15.2°, 15.7°, 16.6°, and 17.7° ( ⁇ 0.2°)
  • the crystal of the compound of formula (4) is a 5C type crystal having at least five of the following peaks in powder X-ray diffraction as a diffraction angle 2 ⁇ : 7.3°, 9.7°, 12.1°, 14.8°, 15.2°, 15.7°, 16.6°, and 17.7° ( ⁇ 0.2°)
  • the crystal of the compound of formula (4) is a 5C type crystal having at least seven of the following peaks in powder X-ray diffraction at a diffraction angle 2 ⁇ : 7.3°, 9.7°, 12.1°, 14.8°, 15.2°, 15.7°, 16.6°, and 17.7° ( ⁇ 0.2°)
  • the crystal of the compound of formula (4) is a 5C type crystal having the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction. 7.3°, 9.7°, 12.1°, 14.8°, 15.2°, 15.7°, 16.6°, and 17.7° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (4) is a 5D type crystal having at least one of the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction: 11.3°, 13.1°, 13.8°, 14.9°, 15.9°, 16.1°, 16.7°, 17.5°, 18.1°, and 18.5° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (4) is a 5D type crystal comprising at least three of the following peaks in powder X-ray diffraction at a diffraction angle 2 ⁇ : 11.3°, 13.1°, 13.8°, 14.9°, 15.9°, 16.1°, 16.7°, 17.5°, 18.1°, and 18.5° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (4) is a 5D type crystal having at least five of the following peaks in powder X-ray diffraction as a diffraction angle 2 ⁇ : 11.3°, 13.1°, 13.8°, 14.9°, 15.9°, 16.1°, 16.7°, 17.5°, 18.1°, and 18.5° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (4) is a 5D type crystal that contains at least seven of the following peaks in powder X-ray diffraction as a diffraction angle 2 ⁇ : 11.3°, 13.1°, 13.8°, 14.9°, 15.9°, 16.1°, 16.7°, 17.5°, 18.1°, and 18.5° ( ⁇ 0.2°)
  • the non-solvated crystal of the compound of formula (4) is a 5D type crystal having the following peaks as a diffraction angle 2 ⁇ in powder X-ray diffraction. 11.3°, 13.1°, 13.8°, 14.9°, 15.9°, 16.1°, 16.7°, 17.5°, 18.1°, and 18.5° ( ⁇ 0.2°)
  • the crystal of the compound of formula (4) is a 5G type crystal having at least one of the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction: 9.4°, 11.0°, 13.4°, 15.0°, 16.1°, 17.8°, 18.1°, 19.7°, 20.8°, and 22.0° ( ⁇ 0.2°)
  • the crystal of the compound of formula (4) is a 5G type crystal that contains at least three of the following peaks in powder X-ray diffraction at a diffraction angle 2 ⁇ : 9.4°, 11.0°, 13.4°, 15.0°, 16.1°, 17.8°, 18.1°, 19.7°, 20.8°, and 22.0° ( ⁇ 0.2°)
  • the crystal of the compound of formula (4) is a 5G type crystal that contains at least five of the following peaks in powder X-ray diffraction at a diffraction angle 2 ⁇ : 9.4°, 11.0°, 13.4°, 15.0°, 16.1°, 17.8°, 18.1°, 19.7°, 20.8°, and 22.0° ( ⁇ 0.2°)
  • the crystal of the compound of formula (4) is a 5G type crystal that contains at least seven of the following peaks in powder X-ray diffraction at a diffraction angle 2 ⁇ : 9.4°, 11.0°, 13.4°, 15.0°, 16.1°, 17.8°, 18.1°, 19.7°, 20.8°, and 22.0° ( ⁇ 0.2°)
  • the crystal of the compound of formula (4) is a 5G type crystal having the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction. 9.4°, 11.0°, 13.4°, 15.0°, 16.1°, 17.8°, 18.1°, 19.7°, 20.8°, and 22.0° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (5) is a 4B type crystal having at least one of the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction: 7.7°, 13.3°, 14.0°, 15.4°, 16.2°, 17.9°, 18.2°, 18.5°, 19.1°, and 20.6° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (5) is a 4B type crystal having at least three of the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction: 7.7°, 13.3°, 14.0°, 15.4°, 16.2°, 17.9°, 18.2°, 18.5°, 19.1°, and 20.6° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (5) is a 4B type crystal having at least five of the following peaks in powder X-ray diffraction at a diffraction angle 2 ⁇ : 7.7°, 13.3°, 14.0°, 15.4°, 16.2°, 17.9°, 18.2°, 18.5°, 19.1°, and 20.6° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (5) is a 4B type crystal having at least seven of the following peaks as a diffraction angle 2 ⁇ in powder X-ray diffraction: 7.7°, 13.3°, 14.0°, 15.4°, 16.2°, 17.9°, 18.2°, 18.5°, 19.1°, and 20.6° ( ⁇ 0.2°)
  • the hydrate crystal of the compound of formula (5) is a 4B type crystal having the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction. 7.7°, 13.3°, 14.0°, 15.4°, 16.2°, 17.9°, 18.2°, 18.5°, 19.1°, and 20.6° ( ⁇ 0.2°)
  • the crystal of the compound of formula (5) is a 4A type crystal having at least one of the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction: 11.5°, 11.8°, 15.7°, 17.2°, 17.5°, 18.1°, 19.5°, 20.3°, 20.5°, and 21.2° ( ⁇ 0.2°)
  • the crystal of the compound of formula (5) is a 4A type crystal having at least three of the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction: 11.5°, 11.8°, 15.7°, 17.2°, 17.5°, 18.1°, 19.5°, 20.3°, 20.5°, and 21.2° ( ⁇ 0.2°)
  • the crystal of the compound of formula (5) is a 4A type crystal having at least five of the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction: 11.5°, 11.8°, 15.7°, 17.2°, 17.5°, 18.1°, 19.5°, 20.3°, 20.5°, and 21.2° ( ⁇ 0.2°)
  • the crystal of the compound of formula (5) is a 4A type crystal having at least seven of the following peaks in powder X-ray diffraction as a diffraction angle 2 ⁇ : 11.5°, 11.8°, 15.7°, 17.2°, 17.5°, 18.1°, 19.5°, 20.3°, 20.5°, and 21.2° ( ⁇ 0.2°)
  • the crystal of the compound of formula (5) is a 4A type crystal having the following peaks at a diffraction angle 2 ⁇ in powder X-ray diffraction. 11.5°, 11.8°, 15.7°, 17.2°, 17.5°, 18.1°, 19.5°, 20.3°, 20.5°, and 21.2° ( ⁇ 0.2°)
  • ⁇ indicating a numerical range includes both ends of the range.
  • a ⁇ B means a numerical range that is equal to or greater than A and equal to or less than B.
  • active ingredients used in pharmaceuticals can be processed by known methods into the optimal shape or properties, i.e., dosage form, according to the method of use or purpose of use.
  • dosage forms include liquid pharmaceutical preparations (liquid preparations) such as injections, suspensions, emulsions, and eye drops, and solid pharmaceutical preparations (solid preparations) such as tablets, powders, fine granules, granules, coated tablets, capsules, dry syrups, lozenges, and suppositories, but are not limited to these.
  • reaction solution was cooled to room temperature, and tert-butyl 8-bromo-2,4-dihydro-1,3-benzoxazine-3-carboxylate (2.65 g, 8.43 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex (0.344 g, 0.422 mmol), potassium carbonate (3.50 g, 25.3 mmol), and water (4.22 mL) were added, and the mixture was stirred at 90°C for 3 hours.
  • the reaction solution was cooled to room temperature, and water and ethyl acetate were added, followed by filtration through Celite.
  • Second step compound 1 4-[3-[2,6-dichloro-4-[(2R)-2,4-dimethylpiperazin-1-yl]benzoyl]-2,4-dihydro-1,3-benzoxazin-8-yl]-5-fluoro-2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)benzoic acid Methyl 4-[3-[2,6-dichloro-4-[(2R)-2,4-dimethylpiperazin-1-yl]benzoyl]-2,4-dihydro-1,3-benzoxazin-8-yl]-5-fluoro-2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)benzoate (18.6 g, 27.2 mmol) in 1-methylpyrrolidin-2-one (186 mL) was added with 8M potassium hydroxide aqueous solution (11.9 mL, 95.0 mmol
  • Second step compound 3-2 7,7-Dimethyl-5,9-dioxa-2-azaspiro[3.5]nonane
  • Benzyl 7,7-dimethyl-5,9-dioxa-2-azaspiro[3.5]nonane-2-carboxylate (3.63 g, 12.5 mmol) in 1,4-dioxane (36.3 mL)
  • 20% palladium hydroxide-activated carbon (wet) (306 mg, 0.436 mmol)
  • the reaction solution was filtered through Celite, washed with 1,4-dioxane, and Concentration gave the title compound as a crude product in 1,4-dioxane solution.
  • Fourth step compound 3 4-[3-[2,6-dichloro-4-(7,7-dimethyl-5,9-dioxa-2-azaspiro[3.5]nonan-2-yl)benzoyl]-2,4-dihydro-1,3-benzoxazin-8-yl]-5-fluoro-2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)benzoic acid
  • methyl 4-[3-[2,6-dichloro-4-(7,7-dimethyl-5,9-dioxa-2-azaspiro[3.5]nonan-2-yl)benzoyl]-2,4-dihydro-1,3-benzoxazin-8-yl]-5-fluoro-2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)benzoato (12.8 g, 17.6 mmol) in tetrahydrofuran (32.0
  • Second step compound 4-2 Methyl 4-[3-[2,6-dichloro-4-(6-methoxy-2-azaspiro[3.3]heptan-2-yl)benzoyl]-2,4-dihydro-1,3-benzoxazine 8-yl]-5-fluoro-2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)benzoate
  • a solution of 2,6-dichloro-4-(6-methoxy-2-azaspiro[3.3]heptan-2-yl)benzoic acid (698 mg, 2.21 mmol) in ethyl acetate (14.0 mL) was added to Ghosez The reagent (0.350 mL, 2.65 mmol) was added.
  • Third step compound 4 4-[3-[2,6-dichloro-4-(6-methoxy-2-azaspiro[3.3]heptan-2-yl)benzoyl]-2,4-dihydro-1,3-benzoxazin-8-yl]-5-fluoro-2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)benzoic acid Methyl 4-[3-[2,6-dichloro-4-(6-methoxy-2-azaspiro[3.3]heptan-2-yl)benzoyl]-2,4-dihydro-1,3-benzoxazin-8-yl]-5-fluoro-2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)benzoato (196 mg, 0.281 mmol) and 8M aqueous potassium hydroxide solution (0.352 mL, 2.81 mmol) in tetrahydrofuran (
  • Second step compound 4 4-[3-[2,6-dichloro-4-(6-methoxy-2-azaspiro[3.3]heptan-2-yl)benzoyl]-2,4-dihydro-1,3-benzoxazin-8-yl]-5-fluoro-2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)benzoic acid
  • methyl 4-[3-[2,6-dichloro-4-(6-methoxy-2-azaspiro[3.3]heptan-2-yl)benzoyl]-2,4-dihydro-1,3-benzoxazin-8-yl]-5-fluoro-2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)benzoato (12.3 g, 17.6 mmol) in tetrahydrofuran (22.0 mL)/ethanol (22.0 mL), 8M aqueous potassium hydroxide
  • Second step compound 5-2 2-Chloro-4-[(2R,5R)-2,4,5-trimethylpiperazin-1-yl]benzoic acid
  • (2R,5R)-1,2,5-trimethylpiperazine (1.63 g, 12.7 mmol) in tetrahydrofuran (18.4 mL) was added with sodium tert-butoxide (2.78 g, 28.9 mmol).
  • 4-Bromo-2-chlorobenzoic acid (2.00 g, 8.49 mmol) and rac-BINAP (0.264 g, 0.425 mmol) in 4-methyltetrahydropyran (6.00 mL) were added.
  • allylpalladium(II) chloride (dimer) (0.0780 g, 0.212 mmol) and rac-BINAP (0.264 g, 0.425 mmol) were added with 4-methyltetrahydropyran (4.00 mL) was added and stirred for 30 minutes.
  • the above prepared solution was added and stirred for 2 hours at 90° C.
  • an aqueous solution of N-acetylcysteine was added and stirred for 3 hours at 45° C.
  • 6M hydrochloric acid and 4-methyltetrahydropyran Ethyl acetate was added to the aqueous layer, and 8M aqueous sodium hydroxide solution was added to perform back extraction.
  • N,N-diisopropylethylamine (16.0 mL, 92.0 mmol) was added, and the mixture was stirred at 25° C. for 1 hour.
  • Ethyl acetate and water were added to the reaction solution, and then, Water, 15% sodium chloride aqueous solution, 8M sodium hydroxide aqueous solution, and 1M hydrochloric acid were added, and the organic layer obtained by extraction was concentrated. 1M hydrochloric acid and ethyl acetate were added to the obtained residue, and back extraction was performed. To the resulting aqueous layer were added 8M aqueous sodium hydroxide solution and 2M hydrochloric acid, followed by extraction with 4-methyltetrahydropyran.
  • Second step compound 6-2 Methyl 4-[3-(4,6-dichloro-2-methylpyridine-3-carbonyl)-2,4-dihydro-1,3-benzoxazin-8-yl]-5-fluoro-2-(3- Oxa-8-azabicyclo[3.2.1]octan-8-yl)benzoate Methyl 4-(3,4-dihydro-2H-1,3-benzoxazin-8-yl)-5-fluoro-2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl
  • the title compound was obtained by the same procedure as in the fifth step of Compound B using benzoyl dihydrochloride and 4,6-dichloro-2-methylpyridine-3-carbonyl chloride, except that N,N-diisopropylethylamine was used. Instead, 4-methylmorpholine was used.
  • LCMS m/z 586 [M+H] + HPLC retention time: 1.30 minutes
  • Fourth step compound 6 4-[3-[4-chloro-6-(7,7-dimethyl-5,9-dioxa-2-azaspiro[3.5]nonan-2-yl)-2-methylpyridine-3-carbonyl]-2,4-dihydro-1,3-benzoxazin-8-yl]-5-fluoro-2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)benzoic acid Methyl 4-[3-[4-chloro-6-(7,7-dimethyl-5,9-dioxa-2-azaspiro[3.5]nonan-2-yl)-2-methylpyridine-3-carbonyl]-2,4-dihydro-1,3-benzoxazin-8-yl]-5-fluoro-2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)benzoato (5.97 g, 8.44 mmol) in te
  • Second step compound 7-2 Ethyl 3-(1,2,3,4-tetrahydroisoquinolin-5-yl)butanoate
  • ethyl (E)-3-(3,4-dihydroisoquinolin-5-yl)but-2-enoate 100 mg, 0.410 mmol
  • 10% palladium on carbon 20.0 mg
  • the solution was stirred under a hydrogen atmosphere for 10 days, filtered, and the filtrate was concentrated to give the title compound as a crude product.
  • Seventh step compound 7-7 5-((R)-4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)-4-oxobutan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carvone Acid tert-butyl Crude (R)-3-(2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinolin-5-yl)butanoic acid and triethylamine (0.499 mL, 3.59 mmol) A solution of (S)-4 in tetrahydrofuran (4.79 mL) was cooled to 0° C., and pivaloyl chloride (0.162 mL, 1.32 mmol) was added thereto, followed by stirring at 0° C.
  • Eighth step compound 7-8 5-((2R,3S)-4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)-3-methyl-4-oxobutan-2-yl)-3,4-dihydroisoquinoline- 2(1H)-Carboxylic acid tert-butyl 5-((R)-4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)-4-oxobutan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carvone
  • a solution of tert-butyl acetate (365 mg, 0.848 mmol) in tetrahydrofuran (4.24 mL) was cooled to ⁇ 78° C., and 1 M sodium bis(trimethylsilyl)amide (1.10 mL, 1.10 mmol) was added dropwise.
  • Example 2-1-3 Compound 1 (30.3 mg) was added with 120 ⁇ L of tetrahydrofuran and dissolved at room temperature. 120 ⁇ L of water was added, and about 0.1 mg of the crystals obtained in Example 2-1-2 was added as seed crystals. After 30 minutes, 60 ⁇ L of water was added. After 130 minutes, 60 ⁇ L of water was added. After 50 minutes, 120 ⁇ L of water was added. After 150 minutes, 120 ⁇ L of water was added. After 80 minutes, 240 ⁇ L of water was added. After 20 hours, the liquid was filtered and dried at room temperature for 24 hours to obtain 27.8 mg of hydrate 1G type crystal powder. The results of powder X-ray diffraction measurement of this powder are shown in FIG. 3, and representative peaks are shown in Table 3 below. The results of TG-DTA measurement are shown in FIG. 4.
  • Example 2-1-4 The 1G type crystal was stored at 34°C and a relative humidity of 60% for about 5 minutes, and powder X-ray diffraction measurement was performed. Then, the relative humidity was changed to 0%, and the crystal was stored for about 60 minutes, and powder X-ray diffraction measurement was performed. From this result, it was confirmed that when the relative humidity was changed from 60% to 0%, the 1G type crystal was transformed into the 1H type crystal, which is a non-solvate. Furthermore, the relative humidity was changed to 30%, and the crystal was stored for about 15 minutes, and powder X-ray diffraction measurement was performed.
  • Example 2-1-5 Acetone (15 ⁇ L) was added to compound 1 (5.6 mg) and stirred. After 5 minutes, acetone (35 ⁇ L) was added. The suspension was filtered to obtain 1K type crystals. The results of powder X-ray diffraction are shown in FIG. 6, and representative peaks are shown in Table 5 below.
  • Example 2-1-6 Compound 1 (10.5 mg) was added with dimethylformamide (40 ⁇ L) and dissolved at 80° C. Water (20 ⁇ L) was added, and 1G type crystal (0.1 mg) was added as a seed crystal, and cooled to room temperature. After that, it was heated to 80° C., water (10 ⁇ L) was added, and cooled to room temperature. It was then further heated to 80° C. and cooled to room temperature. It was further heated to 80° C., water (5 ⁇ L) was added, and cooled to room temperature. It was then further heated to 80° C. and cooled to room temperature. X-ray crystal structure analysis was performed on the obtained crystal. The crystal structure of the obtained 1G type crystal is shown in FIG. 7. In addition, parameters characterizing this crystal are shown in Table 6 below.
  • Example 2-2-1 2-Propanol (15 ⁇ L) was added to compound 4 (3 mg) and the mixture was shaken for 6 days to obtain crystals. The obtained crystals were confirmed to be non-solvated 2A type crystals by powder X-ray diffraction.
  • Example 2-2-2 Ethanol (15 ⁇ L) was added to compound 4 (3 mg) and shaken for 6 days to obtain non-solvated 2B type crystals.
  • the results of powder X-ray diffraction are shown in Figure 8, and representative peaks are shown in Table 7 below.
  • Example 2-2-3 Compound 4 (about 5 mg) was dissolved in acetonitrile (100 ⁇ L) under heating and refluxing conditions, and then cooled to room temperature to obtain crystals. The obtained crystals were confirmed to be non-solvated 2F type crystals by powder X-ray diffraction.
  • Example 2-2-4 Compound 4 (146.8 mg) was added with DMSO (1 mL) and dissolved at 120° C. The mixture was cooled to room temperature, 2-propanol (5 mL) was added, and the crystals obtained in Example 2-2-1 (about 0.1 mg) were added as seed crystals. 2-propanol (10 mL) was further added, and the mixture was stirred for 18 hours, filtered, and the resulting solid was washed with 2-propanol (2 mL). The mixture was dried in vacuum for one day to obtain 125.3 mg of non-solvated 2A type crystals. The results of the powder X-ray diffraction measurement are shown in FIG. 9, and the representative peaks are shown in Table 8 below. The results of the TG-DTA measurement are shown in FIG. 10.
  • Example 2-2-5 Compound 4 (105.8 mg) was added to acetonitrile (5 mL), dissolved under heating under reflux, and cooled to room temperature. This solution was added dropwise to water (15 mL) and stirred overnight to obtain 92.2 mg of non-solvated 2C type crystals.
  • the results of the powder X-ray diffraction measurement are shown in FIG. 11, and representative peaks are shown in Table 9 below.
  • the results of the TG-DTA measurement are shown in FIG. 12.
  • Example 2-2-6 Acetonitrile (900 ⁇ L) was added to compound 4 (29.4 mg), dissolved under heating and refluxing conditions, and then cooled to room temperature. The crystals obtained in Example 2-2-3 (about 0.1 mg) were added as seed crystals, and the mixture was stirred for 3 hours. The powder obtained after filtration was dried in vacuum to obtain 18.9 mg of 2F type crystals. The results of the powder X-ray diffraction measurement are shown in FIG. 13, and the representative peaks are shown in Table 10 below. The results of the TG-DTA measurement are shown in FIG. 14.
  • Example 2-3-1 Ethyl acetate (300 ⁇ L) was added to compound 3 (approximately 30 mg). After 30 minutes, the suspension was partially filtered to obtain 3D type crystals. The results of powder X-ray diffraction measurement are shown in FIG. 15. The remaining suspension was stirred for an additional 15 minutes and then filtered, and the obtained solid was vacuum dried overnight to obtain 3B type crystals. The results of powder X-ray diffraction measurement are shown in FIG. 16. The results of TG-DTA measurement are shown in FIG. 17. Representative peaks of each powder X-ray diffraction measurement are shown in Table 11 below.
  • Example 2-3-2 Compound 3 (29.4 mg) was added with ethanol (300 ⁇ L) and dissolved under heating under reflux. After cooling to room temperature and stirring for 16 hours, the suspension was filtered and subjected to powder X-ray diffraction measurement. The obtained powder was dried in vacuum to obtain non-solvated 3A type crystals. The results of the powder X-ray diffraction measurement are shown in FIG. 18, and the representative peaks are shown in Table 12 below.
  • Example 2-3-3 Methanol (300 ⁇ L) was added to compound 3 (about 30 mg) and stirred at room temperature for about 30 minutes. A portion of the resulting suspension was filtered, and powder X-ray diffraction measurement was performed. The remainder was also filtered, and the solid was isolated and dried in vacuum for one day to obtain non-solvated 3C type crystals. The results of the powder X-ray diffraction measurement are shown in FIG. 19, and representative peaks are shown in Table 13 below. The results of the TG-DTA measurement are shown in FIG. 20.
  • Example 2-4-1 Methyl isobutyl ketone (15 ⁇ L) was added to compound 6 (3 mg) and the mixture was shaken for 3 days. Heptane (15 ⁇ L) was then added and the mixture was shaken for 5 days to obtain 4A-type crystals.
  • the results of the powder X-ray diffraction measurement are shown in FIG. 21, and the representative peaks are shown in Table 14 below.
  • the results of single crystal X-ray crystal structure analysis are shown in Figure 22.
  • the parameters characterizing this crystal are shown in Table 15 below.
  • Example 2-4-3 Acetone (200 ⁇ L) was added to compound 6 (50.1 mg), and the mixture was heated to 60° C. After cooling to room temperature, water (50 ⁇ L) was added. After an additional 5 minutes, water (100 ⁇ L) was added. After an additional 10 minutes, water (250 ⁇ L) was added. After an additional 5 minutes, water (400 ⁇ L) was added. After an additional 5 minutes, water (1200 ⁇ L) was added. After 15 minutes, the suspension was filtered, and powder X-ray diffraction measurement was performed. The suspension was dried at room temperature under normal pressure for 15 hours, and 44.9 mg of 4B type crystals were obtained. The results of the powder X-ray diffraction measurement are shown in FIG. 23, and representative peaks are shown in Table 16 below. The results of the TG-DTA measurement are shown in FIG. 24.
  • Example 2-5-1 Compound 5 (5.4 mg) was added with PEG400 (15 ⁇ L) and heated to 80° C. The mixture was stirred overnight, and water (5 ⁇ L) was added. After another 7 hours, the mixture was cooled to room temperature and stirred for 3 days to obtain crystals. The obtained crystals were confirmed to be hydrate 5A type crystals by powder X-ray diffraction.
  • Example 2-5-3 Compound 5 (about 25 mg) was heated at 110° C. for 1 hour. The mixture was cooled to room temperature and further stored under a condition of 100% relative humidity for 2 hours to obtain hydrate 5E type crystals. The results of powder X-ray diffraction measurement are shown in FIG. 27. The results of TG-DTA measurement are shown in FIG. 28. The obtained 5E type crystals were then vacuum-dried to obtain non-solvate 5D type crystals. The results of powder X-ray diffraction measurement are shown in FIG. 29. Representative peaks of each powder X-ray diffraction measurement are shown in Table 18 below.
  • Example 2-5-4 The 5A type crystal, which is a hydrate, was stored at 25°C and a relative humidity of 95% for 1 hour. It was then stored at a relative humidity of 60% for 1 hour, and powder X-ray diffraction measurement was performed (first time). It was further stored at a relative humidity of 30% for 1 hour, and powder X-ray diffraction measurement was performed. It was further stored at a relative humidity of 20% for 1 hour, and powder X-ray diffraction measurement was performed. It was further stored at a relative humidity of 10% for 1 hour, and powder X-ray diffraction measurement was performed. The results of these powder X-ray diffraction measurements are shown in Figure 30, and representative peaks at each humidity are shown in Table 19 below.
  • Example 2-5-5-5 Acetone (25 ⁇ L) was added to the 5A type crystal (5.0 mg), glass beads were added, and the mixture was shaken at room temperature at 2000 rpm for 7 days to obtain the 5G type crystal.
  • the results of the powder X-ray diffraction measurement are shown in FIG. 32, and the representative peaks are shown in Table 20 below.
  • Example 2-5-7 Acetone (1.3 v/w, 1.1 mL) was added to a methyl ethyl ketone solution (1.4 v/w) of compound 5 (850 mg), and methyl ethyl ketone (1.2 v/w, 1.0 mL) was added. Water (1.6 mL) was added, and 5A type crystals (8.5 mg) were added as seed crystals, and water (1.6 mL) was further added over 30 minutes and stirred for 1 hour. Water (3.2 mL) was added and stirred for 21 hours. Water (3.2 mL) was added over 1 hour and stirred for 3 hours, and water (3.2 mL) was further added over 1 hour and stirred for 17 hours and 30 minutes.
  • Example 2-5-8 The 5A type crystals prepared by the method described in Example 2-5-7 were stored at 25°C and a relative humidity of 5% or 10% for 1 hour, and powder X-ray diffraction measurements were performed. From these results, it was confirmed that the 5A type crystals, which are hydrates, transition to the 5C type crystals when the relative humidity is changed to around 10% or lower.
  • the results of the powder X-ray diffraction measurements are shown in Figure 35, and representative peaks are shown in Table 22 below.
  • Example 2-5-9 The 5C type crystals prepared by the method described in Example 2-5-8 were stored at 25°C at a relative humidity of about 30% or higher for 1 hour, and powder X-ray diffraction measurements were performed at each relative humidity. From these results, it was confirmed that when the relative humidity was changed to about 30% or higher, the 5C type crystals were transformed into the 5J type crystals, which are hydrates. It was also confirmed that the peak positions of the powder X-ray diffraction pattern of the 5J type crystals shifted slightly depending on the relative humidity. The results of the powder X-ray diffraction measurements are shown in Figure 36, and representative peaks are shown in Table 23 below.
  • the single crystal X-ray structure analysis was carried out under the following conditions.
  • Measurement device XtaLAB Synergy Custom with a VariMax Cu diffractometer or Rigaku R-AXIS RAPID-II with a VariMax Cu diffractometer (manufactured by Rigaku Corporation)
  • Radiation source CuK ⁇ Tube voltage/current: 40 kV/30 mA Temperature: -180°C or room temperature.
  • the measurement was performed with a strategy and exposure time that was believed to provide diffraction spots sufficient for structural analysis.
  • the initial structure determination for structural analysis was performed using a direct method (SHELXT2014/5 or SHELXT2018/2), and the structure refinement was performed using the full-matrix least-squares method (SHELXL2017/1).
  • Example 2 The simultaneous thermogravimetry and differential thermal analysis (TG-DTA) in Example 2 was carried out under the following conditions: The onset temperature was determined from the endothermic peak and was taken as the melting point. Apparatus: STA7200RV (Hitachi High-Tech Science Corporation) Measurement atmosphere: nitrogen Temperature increase conditions: The temperature was increased from 30° C. to 350° C. at a rate of 10° C./min.
  • the luciferase activity in each well was converted to a reaction rate (%), with the luciferase activity when Compound 2 or Compound 7 was applied at a concentration of 3.75 ⁇ M being taken as 100%.
  • a dose-response curve was prepared for each example compound, and the 50% effective concentration (EC 50 ) was calculated. The results are shown in Table 24. These results demonstrate that the compounds of the present invention have an Nrf2 activation effect in vitro.
  • the present invention provides a crystal of a low molecular weight compound having Nrf2 activation activity, or a salt thereof, or a solvate thereof.
  • the present invention also provides a medicine for the prevention and/or treatment of various diseases, such as neurodegenerative diseases, pulmonary diseases, and renal diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
PCT/JP2024/022040 2023-06-19 2024-06-18 Nrf2活性化作用を有する含窒素複素環化合物の結晶 Ceased WO2024262491A1 (ja)

Priority Applications (7)

Application Number Priority Date Filing Date Title
KR1020257042624A KR20260023529A (ko) 2023-06-19 2024-06-18 Nrf2 활성화 작용을 갖는 질소 함유 헤테로고리 화합물의 결정
IL324833A IL324833A (en) 2023-06-19 2024-06-18 Crystal of a nitrogen-containing heterocyclic compound with an Nrf2 activating effect
EP24825892.3A EP4696692A1 (en) 2023-06-19 2024-06-18 Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect
AU2024314540A AU2024314540A1 (en) 2023-06-19 2024-06-18 Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect
CN202480033461.0A CN121152792A (zh) 2023-06-19 2024-06-18 具有Nrf2活化作用的含氮杂环化合物的晶体
JP2025528066A JP7904995B2 (ja) 2023-06-19 2024-06-18 Nrf2活性化作用を有する含窒素複素環化合物の結晶
MX2025014082A MX2025014082A (es) 2023-06-19 2025-11-25 Cristal de compuesto heterociclico que contiene nitrogeno que tiene un efecto de activacion del factor 2 relacionado con el factor nuclear eritroide 2 (nrf2)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023100075 2023-06-19
JP2023-100075 2023-06-19

Publications (1)

Publication Number Publication Date
WO2024262491A1 true WO2024262491A1 (ja) 2024-12-26

Family

ID=93935419

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2024/022040 Ceased WO2024262491A1 (ja) 2023-06-19 2024-06-18 Nrf2活性化作用を有する含窒素複素環化合物の結晶

Country Status (9)

Country Link
EP (1) EP4696692A1 (cg-RX-API-DMAC7.html)
JP (1) JP7904995B2 (cg-RX-API-DMAC7.html)
KR (1) KR20260023529A (cg-RX-API-DMAC7.html)
CN (1) CN121152792A (cg-RX-API-DMAC7.html)
AU (1) AU2024314540A1 (cg-RX-API-DMAC7.html)
IL (1) IL324833A (cg-RX-API-DMAC7.html)
MX (1) MX2025014082A (cg-RX-API-DMAC7.html)
TW (1) TW202504613A (cg-RX-API-DMAC7.html)
WO (1) WO2024262491A1 (cg-RX-API-DMAC7.html)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065478A1 (en) 1998-06-19 1999-12-23 Trustees Of Dartmouth College Therapeutic compositions and methods of use
WO2014176415A1 (en) 2013-04-24 2014-10-30 Abbvie Inc. 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
WO2016090154A1 (en) 2014-12-04 2016-06-09 Biogen Ma Inc. Multiple sclerosis treatment regimen using dimethyl fumarate
WO2018181345A1 (ja) * 2017-03-28 2018-10-04 武田薬品工業株式会社 複素環化合物
WO2020165776A1 (en) 2019-02-15 2020-08-20 Glaxosmithkline Intellectual Property Development Limited Hydroxypyridoxazepines as nrf2 activators
WO2020241853A1 (ja) * 2019-05-31 2020-12-03 宇部興産株式会社 ベンゾトリアゾール誘導体
CN114507181A (zh) * 2020-11-17 2022-05-17 中国医学科学院药物研究所 含5-取代四氢异喹啉的丙酸类化合物、其药物组合物和应用
JP2023038270A (ja) * 2018-08-20 2023-03-16 ヤンセン ファーマシューティカ エヌ.ベー. KEAP1-Nrf2タンパク質-タンパク質相互作用の阻害剤
JP2023524207A (ja) * 2020-04-22 2023-06-09 シーフォーエックス・ディスカバリー・リミテッド Nrf2活性化剤としてのテトラヒドロイソキノリン化合物
WO2023132369A1 (ja) * 2022-01-07 2023-07-13 中外製薬株式会社 Nrf2活性化作用を有する含窒素複素環化合物

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065478A1 (en) 1998-06-19 1999-12-23 Trustees Of Dartmouth College Therapeutic compositions and methods of use
WO2014176415A1 (en) 2013-04-24 2014-10-30 Abbvie Inc. 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
WO2016090154A1 (en) 2014-12-04 2016-06-09 Biogen Ma Inc. Multiple sclerosis treatment regimen using dimethyl fumarate
WO2018181345A1 (ja) * 2017-03-28 2018-10-04 武田薬品工業株式会社 複素環化合物
JP2023038270A (ja) * 2018-08-20 2023-03-16 ヤンセン ファーマシューティカ エヌ.ベー. KEAP1-Nrf2タンパク質-タンパク質相互作用の阻害剤
WO2020165776A1 (en) 2019-02-15 2020-08-20 Glaxosmithkline Intellectual Property Development Limited Hydroxypyridoxazepines as nrf2 activators
JP2022520442A (ja) * 2019-02-15 2022-03-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Nrf2活性剤としてのヒドロキシピリドキシアゼピン
WO2020241853A1 (ja) * 2019-05-31 2020-12-03 宇部興産株式会社 ベンゾトリアゾール誘導体
JP2023524207A (ja) * 2020-04-22 2023-06-09 シーフォーエックス・ディスカバリー・リミテッド Nrf2活性化剤としてのテトラヒドロイソキノリン化合物
CN114507181A (zh) * 2020-11-17 2022-05-17 中国医学科学院药物研究所 含5-取代四氢异喹啉的丙酸类化合物、其药物组合物和应用
WO2023132369A1 (ja) * 2022-01-07 2023-07-13 中外製薬株式会社 Nrf2活性化作用を有する含窒素複素環化合物

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AM J NEPHROL, vol. 39, 2014, pages 499 - 508
MED CHEM COMMUN, vol. 8, 2017, pages 286 - 294
MEDICINAL CHEMISTRY RESEARCH, vol. 29, 2020, pages 846 - 867
NARAYANAN, DILIP ET AL.: "Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by Fragment-Based Drug Discovery", J. MED. CHEM., vol. 65, 2022, pages 14481 - 14526, XP093183406, DOI: 10.1021/acs.jmedchem.2c00830 *
NATURE REVIEWS DRUG DISCOVERY, vol. 18, 2019, pages 295 - 317
NEURODEGENR DIS MANAG, vol. 7, 2017, pages 97 - 100
OXYDATIVE MEDICINE AND CELLULAR LONGEVITY, vol. 7090534, 2019, pages 1 - 17
OXYDATIVE MEDICINE AND CELLULAR LONGEVITY, vol. 9410952, 2020, pages 1 - 22

Also Published As

Publication number Publication date
TW202504613A (zh) 2025-02-01
JP7904995B2 (ja) 2026-08-13
IL324833A (en) 2026-01-01
MX2025014082A (es) 2026-01-07
AU2024314540A1 (en) 2025-11-27
KR20260023529A (ko) 2026-02-20
EP4696692A1 (en) 2026-02-18
JPWO2024262491A1 (cg-RX-API-DMAC7.html) 2024-12-26
CN121152792A (zh) 2025-12-16

Similar Documents

Publication Publication Date Title
CN103694236B (zh) 一种嘧啶骨架具有刺猬通路拮抗剂活性的抗肿瘤化合物
AU2015222584B2 (en) 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom
JP7470058B2 (ja) 複素環化合物
CN117143175A (zh) 靶向sos1蛋白泛素化调节的化合物及其制备方法和应用
WO2018010514A1 (zh) 作为fgfr抑制剂的杂环化合物
JP7175481B2 (ja) ベンゾイソオキサゾール化合物
JP2024505732A (ja) ピリドピリミジノン系誘導体及びその製造方法と使用
CN111148744B (zh) 作为mglur7调节剂的新的杂环化合物
CN103923085B (zh) 具有刺猬通路拮抗剂活性的吡啶杂环化合物及其用途
WO2023005267A1 (zh) 一种苯并[b]硒吩类STING调控剂、其制备方法及用途
WO2019189555A1 (ja) 複素環化合物
WO2018235838A1 (ja) 複素環化合物
JP2017521489A (ja) ピリミジン化合物およびその使用方法
CN102757448B (zh) 大环类激酶抑制剂化合物、制备方法及其作为药物的应用
JP5847362B1 (ja) シクロヘキシルピリジン誘導体
CA3291766A1 (en) Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect
TW202504613A (zh) 具有Nrf2活化作用之含氮雜環化合物的結晶
CN110709401A (zh) 杂环化合物
CN108117551B (zh) 取代(1H-吡唑[3,4-b]吡啶)脲类化合物及其抗肿瘤用途
KR101418078B1 (ko) mGluR5 길항제로서의 2-(치환된에티닐)퀴놀린 유도체
TW202604504A (zh) 含氮並環化合物、含其的藥物組合物及其應用
WO2023082052A1 (zh) 环状2-氨基嘧啶类化合物及其用途
CN111377906A (zh) 取代的吡嗪化合物及其制备方法和用途
NZ795495A (en) Aminothiazole compounds as c-Kit inhibitors
HK1234394B (en) Cyclohexyl pyridine derivative

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24825892

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: AU2024314540

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2024825892

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2024825892

Country of ref document: EP

Effective date: 20251113

ENP Entry into the national phase

Ref document number: 2025528066

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2024825892

Country of ref document: EP

Effective date: 20251113

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025024594

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: MX/A/2025/014082

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2024314540

Country of ref document: AU

Date of ref document: 20240618

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2024825892

Country of ref document: EP

Effective date: 20251113

ENP Entry into the national phase

Ref document number: 2024825892

Country of ref document: EP

Effective date: 20251113

ENP Entry into the national phase

Ref document number: 2024825892

Country of ref document: EP

Effective date: 20251113

ENP Entry into the national phase

Ref document number: 2024825892

Country of ref document: EP

Effective date: 20251113

ENP Entry into the national phase

Ref document number: 2024825892

Country of ref document: EP

Effective date: 20251113

ENP Entry into the national phase

Ref document number: 2024825892

Country of ref document: EP

Effective date: 20251113

WWP Wipo information: published in national office

Ref document number: MX/A/2025/014082

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2024825892

Country of ref document: EP

Effective date: 20251113

WWE Wipo information: entry into national phase

Ref document number: 202690038

Country of ref document: EA

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2024825892

Country of ref document: EP